AptarGroup (ATR) 10-K 7 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 03, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 301
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction Flag	false
Entity Shell Company	false
Entity Public Float			$ 9,392,860,942
Entity Common Stock, Shares Outstanding		66,495,293
Documents Incorporated by Reference	Portions of the definitive Proxy Statement to be delivered to stockholders in connection with the Annual Meeting of Stockholders to be held May 7, 2025 are incorporated by reference into Part III of this report.
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0000896622
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Chicago, Illinois
Auditor Firm ID	238

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net Sales	$ 3,582,890	$ 3,487,450	$ 3,322,249
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	2,227,381	2,224,051	2,158,411
Selling, Research & Development and Administrative:	582,226	565,783	544,262
Depreciation and amortization	263,784	248,593	233,706
Restructuring initiatives	13,002	45,004	6,597
Total Operating Expenses	3,086,393	3,083,431	2,942,976
Operating Income	496,497	404,019	379,273
Other (Expense) Income:
Interest expense	(43,898)	(40,418)	(40,827)
Interest income	12,101	4,373	2,700
Net investment gain (loss)	1,713	1,413	(2,110)
Equity in results of affiliates	87	2,226	467
Miscellaneous income (expense), net	3,265	3,212	(4,799)
Total Other Expense	(26,732)	(29,194)	(44,569)
Income before Income Taxes	469,765	374,825	334,704
Provision for Income Taxes	95,587	90,649	95,149
Net Income	374,178	284,176	239,555
Net Loss (Income) Attributable to Noncontrolling Interests	363	311	(267)
Net Income Attributable to AptarGroup, Inc.	$ 374,541	$ 284,487	$ 239,288
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 5.65	$ 4.34	$ 3.66
Diluted (in dollars per share)	5.53	4.25	3.59
Dividends per Common Share (in dollars per share)	$ 1.72	$ 1.58	$ 1.52

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 374,178	$ 284,176	$ 239,555
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	(145,807)	48,946	(80,431)
Changes in derivative gains (losses), net of tax	7,813	(10,086)	(6,620)
Defined benefit pension plan, net of tax
Actuarial gain (loss), net of tax	17,043	(6,711)	54,149
Amortization of prior service cost included in net income, net of tax	258	130	130
Amortization of net loss included in net income, net of tax	112	641	6,256
Total defined benefit pension plan, net of tax	17,413	(5,940)	60,535
Total other comprehensive (loss) income	(120,581)	32,920	(26,516)
Comprehensive Income	253,597	317,096	213,039
Comprehensive Loss (Income) Attributable to Noncontrolling Interests	438	(205)	924
Comprehensive Income Attributable to AptarGroup, Inc.	$ 254,035	$ 316,891	$ 213,963

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Assets
Cash and equivalents	$ 223,844	$ 223,643
Short-term investments	2,337	0
Accounts and notes receivable, less current expected credit loss ("CECL") of $15,785 in 2024 and $16,217 in 2023	658,057	677,822
Inventories	461,807	513,053
Prepaid and other	132,338	134,761
Total Current Assets	1,478,383	1,549,279
Land	28,172	30,090
Buildings and improvements	751,813	748,897
Machinery and equipment	3,143,236	3,183,097
Property, Plant and Equipment, Gross	3,923,221	3,962,084
Less: Accumulated depreciation	(2,476,071)	(2,484,021)
​Property, Plant and Equipment, Net	1,447,150	1,478,063
Investments in equity securities	146,269	49,203
Goodwill	936,256	963,418
Intangible assets, net	254,769	283,211
Operating lease right-of-use assets	64,213	59,074
Miscellaneous	105,238	69,642
Total Other Assets	1,506,745	1,424,548
Total Assets	4,432,278	4,451,890
Liabilities and Stockholders’ Equity
Revolving credit facility and overdrafts	176,035	81,794
Current maturities of long-term obligations, net of unamortized debt issuance costs	162,250	376,426
Accounts payable, accrued and other liabilities	729,996	793,089
Total Current Liabilities	1,068,281	1,251,309
Long-Term Obligations, net of unamortized debt issuance costs	688,066	681,188
Deferred income taxes	14,259	19,016
Retirement and deferred compensation plans	62,210	62,795
Operating lease liabilities	49,716	45,267
Deferred and other non-current liabilities	63,822	71,017
Commitments and contingencies - (See Note 13)	0	0
​Total Deferred Liabilities and Other	190,007	198,095
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 72.5 and 71.7 million shares issued as of December 31, 2024 and 2023, respectively	725	717
Capital in excess of par value	1,125,882	1,044,429
Retained earnings	2,370,537	2,109,816
Accumulated other comprehensive loss	(429,475)	(308,734)
Less: Treasury stock at cost, 6.0 and 5.8 million shares as of December 31, 2024 and 2023, respectively	(595,781)	(539,404)
Total AptarGroup, Inc. Stockholders’ Equity	2,471,888	2,306,824
Noncontrolling interests in subsidiaries	14,036	14,474
Total Stockholders’ Equity	2,485,924	2,321,298
Total Liabilities and Stockholders’ Equity	$ 4,432,278	$ 4,451,890

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts and notes receivable, less current expected credit loss (in dollars)	$ 15,785	$ 16,217
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199,000,000	199,000,000
Common stock, shares issued (in shares)	72,500,000	71,700,000
Treasury stock, shares (in shares)	6,000,000	5,800,000

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss)Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Balance at beginning of period at Dec. 31, 2021	$ 1,984,600	$ 1,789,413	$ (316,041)	$ 704	$ (421,203)	$ 916,534	$ 15,193
Increase (Decrease) in Stockholders' Equity
Net income	239,555	239,288					267
Foreign currency translation adjustments	(80,431)		(79,240)				(1,191)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	60,535		60,535
Changes in derivative gains (losses), net of tax	(6,620)		(6,620)
Stock awards and option exercises	62,152			5	10,063	52,084
Cash dividends declared on common stock	(99,461)	(99,461)
Treasury stock purchased	(92,126)				(92,126)
Balance at end of period at Dec. 31, 2022	2,068,204	1,929,240	(341,366)	709	(503,266)	968,618	14,269
Increase (Decrease) in Stockholders' Equity
Net income	284,176	284,487					(311)
Foreign currency translation adjustments	48,946	(228)	48,658				516
Changes in unrecognized pension gains (losses) and related amortization, net of tax	(5,940)		(5,940)
Changes in derivative gains (losses), net of tax	(10,086)		(10,086)
Stock awards and option exercises	87,233			8	11,414	75,811
Cash dividends declared on common stock	(103,683)	(103,683)
Treasury stock purchased	(47,552)				(47,552)
Balance at end of period at Dec. 31, 2023	2,321,298	2,109,816	(308,734)	717	(539,404)	1,044,429	14,474
Increase (Decrease) in Stockholders' Equity
Net income	374,178	374,541					(363)
Foreign currency translation adjustments	(145,807)	235	(145,967)				(75)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	17,413		17,413
Changes in derivative gains (losses), net of tax	7,813		7,813
Stock awards and option exercises	93,722			8	12,261	81,453
Cash dividends declared on common stock	(114,055)	(114,055)
Treasury stock purchased	(68,638)				(68,638)
Balance at end of period at Dec. 31, 2024	$ 2,485,924	$ 2,370,537	$ (429,475)	$ 725	$ (595,781)	$ 1,125,882	$ 14,036

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net income	$ 374,178	$ 284,176	$ 239,555
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	219,667	203,873	190,132
Amortization	44,117	44,720	43,574
Stock-based compensation	47,650	41,293	40,937
Provision for CECL	1,016	8,077	3,213
(Gain) loss on disposition of fixed assets	(52)	(3,584)	397
Net (gain) loss on remeasurement of equity securities	(1,713)	(1,413)	2,110
Deferred income taxes	(21,406)	(19,883)	(12,106)
Defined benefit plan expense	12,049	14,198	24,560
Equity in results of affiliates	(87)	(2,226)	(467)
Impairment loss	254	257	307
Change in fair value of contingent consideration	0	0	(8,598)
Changes in balance sheet items, excluding effects from foreign currency adjustments and acquisitions:
Accounts and other receivables	(18,079)	15,431	(27,937)
Inventories	21,901	(10,641)	(60,354)
Prepaid and other current assets	(2,368)	(3,900)	(6,787)
Accounts payable, accrued and other liabilities	(23,705)	14,596	55,098
Income taxes payable	4,064	(8,301)	17,081
Retirement and deferred compensation plan liabilities	(14,259)	2,984	(13,093)
Other changes, net	186	(4,418)	(9,005)
Net Cash Provided by Operations	643,413	575,239	478,617
Cash Flows from Investing Activities:
Capital expenditures	(276,481)	(312,342)	(310,427)
Proceeds from government grants	0	0	27,795
Proceeds from sale of property, plant and equipment	1,506	5,348	93
Maturity of short-term investments	0	0	740
Purchase of short-term investments	(2,242)	0	0
Acquisition of business, net of cash acquired and release of escrow	0	(16,570)	(4,100)
Acquisition of intangible assets, net	(17,709)	(6,061)	(5,189)
Investment in equity securities	(99,055)	0	0
Proceeds from sale of investment in equity securities	0	5,604	1,599
Notes receivable, net	(2,740)	(442)	(6,153)
Net Cash Used by Investing Activities	(396,721)	(324,463)	(295,642)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	22,302	25,531	39,944
Repayments of notes payable and overdrafts	(23,344)	(28,643)	(38,837)
Proceeds and (repayments) of short term revolving credit facility, net	108,848	76,966	(143,055)
Proceeds from long-term obligations	168,581	403	412,021
Repayments of long-term obligations	(373,847)	(125,809)	(265,085)
Payment of contingent consideration obligation	0	(22,750)	0
Dividends paid	(114,055)	(103,683)	(99,461)
Credit facility costs	0	0	(4,009)
Proceeds from stock option exercises	54,809	53,983	28,512
Purchase of treasury stock	(68,638)	(47,552)	(92,126)
Net Cash Used by Financing Activities	(225,344)	(171,554)	(162,096)
Effect of Exchange Rate Changes on Cash	(21,147)	2,189	(1,072)
Net Increase in Cash and Equivalents and Restricted Cash	201	81,411	19,807
Cash and Equivalents and Restricted Cash at Beginning of Period	224,143	142,732	122,925
Cash and Equivalents and Restricted Cash at End of Period	224,344	224,143	142,732
Supplemental Cash Flow Disclosure:
Interest paid	43,520	39,599	35,509
Income taxes paid	89,374	111,994	87,529
Restricted cash included in the line item prepaid and other on the Consolidated Balance Sheets as shown below represents amounts held in escrow
Cash and equivalents	223,844	223,643	141,732
Restricted cash included in prepaid and other	500	500	1,000
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 224,344	$ 224,143	$ 142,732

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. AptarGroup’s organizational structure consists of three market-focused business segments which are Aptar Pharma, Aptar Beauty and Aptar Closures. This is a strategic structure which allows us to better serve our customers and position us for long-term profitable growth. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentine peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the fourth quarter of 2023, we utilized the Blue Chip Swap and recognized a loss due to devaluation of approximately $2.5 million. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues at and for the year ended December 31, 2024. ACCOUNTING ESTIMATES The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. CASH AND CASH EQUIVALENTS We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents. ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES At December 31, 2024, we reported $658.1 million of accounts receivable, net of CECL of $15.8 million. The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Changes in CECL were not material for the year ended December 31, 2024. INVENTORIES Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead. ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of December 31, 2024, one building is held for sale and expected to be sold during 2025. ACQUISITIONS We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes significant estimates and assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment. INVESTMENTS IN EQUITY SECURITIES We account for our 20% to 50% owned investments using the equity method. Under the equity method, we initially record our investment at cost and our interest in the net assets of the investee is included in the equity method investment on the Consolidated Balance Sheets. We recognize our equity in earnings in our equity method affiliates on a one-month lag basis and record our proportionate share of each investee's net income or loss into earnings after the date of investment, the adjustment of basis difference initially recognized and the other comprehensive income allocated to us from the investee. We evaluate the equity method investments for impairment under ASC 323. An impairment loss on the equity method investments is recognized in earnings when the decline in value is determined to be other-than-temporary. Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception. There were no dividends received from affiliated companies in 2024, 2023 and 2022. PROPERTY AND DEPRECIATION Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment. FINITE-LIVED INTANGIBLE ASSETS Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years. IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In those circumstances, we perform undiscounted operating cash flow analyses for asset groups at the lowest level for which cash flows are separately identifiable to determine if an impairment exists. Any impairment loss is calculated as the excess of the asset’s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. GOODWILL The Company has evaluated the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arose in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires significant judgment and the use of estimates and assumptions related to projected revenue growth rates, projected EBITDA margins, the terminal growth factor, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate. Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management has performed this qualitative assessment as of October 1, 2024 and October 1, 2023 for each of our reporting units. Due to the realignment of the Beauty and Closures segments, management determined it appropriate to calculate the fair value of both reporting units and compare with their associated carrying amounts as of January 1, 2023. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for injectables, and the passage of time from our prior Step 1 analysis over the other pharma reporting unit, management determined it appropriate to calculate the fair value of both reporting units and compare with their associated carrying amounts as of October 1, 2024. Based on our qualitative and quantitative analysis performed over the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction. PURCHASE OF TREASURY STOCK During 2024, 2023 and 2022, we repurchased 433 thousand, 399 thousand and 860 thousand shares, respectively, all of which were returned to treasury stock. If retired, common stock is reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings. RESEARCH & DEVELOPMENT EXPENSES Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred. These costs amounted to $96.1 million, $92.8 million and $93.5 million in 2024, 2023 and 2022, respectively. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany, and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements. We have elected to include amounts paid for transferable, non-refundable U.S. energy credits as cash taxes paid in our Consolidated Statements of Cash Flows. TRANSLATION OF FOREIGN CURRENCIES The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented losses of $2.0 million, $7.3 million and $7.2 million in 2024, 2023 and 2022, respectively. STOCK-BASED COMPENSATION Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur. See Note 16 – Stock-Based Compensation for more information. REVENUE RECOGNITION At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results. See specific discussions about methods of accounting for control transfers of product, tooling and service contract sales in Note 2 – Revenue. LEASES We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in accounts payable accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise). Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability. GOVERNMENT GRANTS We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost. During 2022, we received a $10.5 million government grant to be used toward the expansion of an existing injectables facility, which is reported within the investing section of the Consolidated Statements of Cash Flows to support the delivery of components for COVID-19 and other vaccines. The French government will fund approximately $14.0 million for the expansion of the facility, for which there is no clawback option. During 2022, we received $17.3 million in government grants to be used toward the construction of a new facility in Alabama, which is reported within the investing section of the Consolidated Statements of Cash Flows. This award will support expanded domestic production capacity for our active material science solutions proprietary Activ-Film technology, which is used to protect and enhance COVID-19 test kit integrity and accuracy. Under the terms of the grant agreement, the U.S. government will fund approximately $19 million to build an operating facility, for which there is no clawback provision, in exchange for the new facility to be on standby for the government for a period of 16 months after construction. SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows. As of December 31, 2024 and 2023, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities 2024 2023 SCF obligations outstanding at the beginning of the year $ 36,309 $ 30,833 Additions 160,847 163,591 Settlements (162,755) (158,115) SCF obligations outstanding at the end of the year $ 34,401 $ 36,309 Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us. ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("DISE"), which requires the disaggregation of certain expenses in the notes to the financial statements, to provide enhanced transparency into the expense captions presented on the face of the income statement. ASU 2024-03 will be effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective adoption. We are evaluating the impact of the standard on our disclosures in the Consolidated Financial Statements. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and is required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We adopted this guidance in the fourth quarter of 2024. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 18 - Segment Information for further discussion. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We adopted this guidance in the fourth quarter of 2024. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from LIBOR to SOFR for USD balances under our amended revolving credit facility. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.

REVENUE

REVENUE	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE In prior years, our geographic revenue disclosure was based on shipped from location. Beginning in 2024, we have started to report our geographic sales based on shipped to locations to give the reader a better understanding of the geographies we serve. Revenue by segment and geography based on shipped to locations for the years ended December 31, 2024, 2023 and 2022 were as follows: For the Year Ended December 31, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 806,606 $ 556,642 $ 47,124 $ 232,780 $ 1,643,152 Aptar Beauty 745,198 241,115 155,692 83,725 1,225,730 Aptar Closures 218,064 347,733 83,376 64,835 714,008 Total $ 1,769,868 $ 1,145,490 $ 286,192 $ 381,340 $ 3,582,890 For the Year Ended December 31, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 779,929 $ 495,057 $ 52,074 $ 193,933 $ 1,520,993 Aptar Beauty 806,963 219,760 152,963 88,011 1,267,697 Aptar Closures 218,833 336,315 84,146 59,466 698,760 Total $ 1,805,725 $ 1,051,132 $ 289,183 $ 341,410 $ 3,487,450 For the Year Ended December 31, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 683,217 $ 446,821 $ 38,483 $ 192,735 $ 1,361,256 Aptar Beauty 715,797 280,023 134,883 91,832 1,222,535 Aptar Closures 217,162 378,503 79,482 63,311 738,458 Total $ 1,616,176 $ 1,105,347 $ 252,848 $ 347,878 $ 3,322,249 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2023 Balance as of December 31, 2024 Increase/ Contract asset (current) $ 18,033 $ 12,571 $ (5,462) Contract liability (current) 60,507 64,425 3,918 Contract liability (long-term) 37,756 40,551 2,795 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during 2024 against contract liabilities is $122.9 million, including $54.3 million relating to contract liabilities at the beginning of the year. Current contract assets and long-term contract assets are included within the prepaid and other and miscellaneous assets, respectively, while current contract liabilities and long-term contract liabilities are included within accounts payable, accrued and other liabilities and deferred and other non-current liabilities, respectively, within our Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identifies reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which it will be entitled. Product Sales We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress toward completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of its customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress toward completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of December 31, 2024 or December 31, 2023. Service Sales We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation. Royalty Revenue We determine the amount and timing of royalty revenue based on our contractual agreements with customers. These contracts contain variable consideration which primarily relate to sales- or usage-based royalties related to the license of intellectual property in collaboration and license contracts. For sales- and usage-based royalties, ASC 606 provides an exception to estimating variable consideration. Under this exception, we recognize revenues from sales- or usage-based royalty revenue at the later of when the sales or usage occurs or the satisfaction (or partial satisfaction) of the performance obligation to which the royalty has been allocated. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables. Practical Expedients Significant financing component: We elected not to adjust the promised consideration for the time value of money for contracts where the difference between the time of payment and performance is one year or less. Remaining performance obligations: We elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for our contracts that are one year or less, as the revenue is expected to be recognized within the next year. In addition, we have elected not to disclose the expected consideration related to performance obligations where we recognize revenue in the amount it has a right to invoice (e.g., usage-based pricing terms).

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: 2024 2023 Raw materials $ 133,885 $ 145,798 Work in process 161,350 176,191 Finished goods 166,572 191,064 Total $ 461,807 $ 513,053

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the year ended December 31, 2024 are as follows by reporting segment: Aptar Aptar Aptar Total Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632 Reclassification due to segment change — (39,472) 39,472 — Acquisition — 4,603 114 4,717 Foreign currency exchange effects 9,705 2,955 409 13,069 Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects (20,213) (5,811) (1,138) (27,162) Balance as of December 31, 2024 $ 488,234 $ 281,286 $ 166,736 $ 936,256 Effective January 1, 2023, we realigned two of our segment, allowing us to better serve our customers and position us for long-term profitable growth; see Note 18 - Segment Information for additional information. As a result of this segment realignment, we reassigned a total of $39.5 million of goodwill from the Beauty reporting unit to the Closures reporting unit using the relative fair value approach. We have completed the annual impairment analysis of our reporting units as of October 1, 2024. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for injectables and the passage of time from our prior Step 1 analysis over the other pharma reporting unit, management determined it appropriate to calculate the fair value of both reporting units and compare with their associated carrying amounts as of October 1, 2024. We estimated the fair values of the affected businesses based upon the present value of their estimated future cash flows. Our determination of fair value involved judgment and the use of significant estimates and assumptions, including assumptions regarding the projected revenue growth rates, projected EBITDA margins, as well as the discount rate to calculate estimated future cash flows. We believe that our assumptions used in discounting future cash flows are appropriate. Based on our review of macroeconomic, industry, and market events and circumstances as well as the overall financial performance of the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts. No impairment was recognized during the years ended December 31, 2024, 2023 or 2022. The table below shows a summary of intangible assets for the years ended December 31, 2024 and 2023. 2024 2023 Weighted Average Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 12.6 $ 18,333 $ (2,343) $ 15,990 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.2 137,444 (80,171) 57,273 142,837 (70,520) 72,317 Customer relationships 13.6 303,502 (145,772) 157,730 308,889 (124,648) 184,241 Trademarks and trade names 8.0 42,882 (36,450) 6,432 43,932 (33,368) 10,564 License agreements and other 19.5 26,318 (8,974) 17,344 17,213 (6,732) 10,481 Total intangible assets 13.3 $ 528,479 $ (273,710) $ 254,769 $ 520,233 $ (237,022) $ 283,211 During the year ended December 31, 2024, we purchased $17.7 million of intangibles primarily associated with the purchase of patents of $12.4 million and other intangible assets. Aggregate amortization expense for the intangible assets above for the years ended December 31, 2024, 2023 and 2022 was $44,117, $44,720 and $43,574, respectively. Future estimated amortization expense for the years ending December 31 is as follows: 2025 $ 42,075 2026 40,923 2027 33,358 2028 29,374 2029 27,283 2030 and thereafter 81,756 Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of December 31, 2024.

ACCOUNTS PAYABLE, ACCRUED AND O

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES	ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES At December 31, 2024 and 2023, accounts payable, accrued and other liabilities consisted of the following: 2024 2023 Accounts payable, principally trade $ 295,967 $ 328,571 Accrued employee compensation costs 211,441 222,010 Customer deposits and other unearned income 64,425 60,507 Other accrued liabilities 158,163 182,001 Total $ 729,996 $ 793,089

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income before income taxes consists of: Years Ended December 31, 2024 2023 2022 United States $ 99,573 $ 49,681 $ 65,350 International 370,192 325,144 269,354 Total $ 469,765 $ 374,825 $ 334,704 The provision (benefit) for income taxes is composed of: Years Ended December 31, 2024 2023 2022 Federal: Current $ 10,933 $ 11,777 $ 12,791 Deferred (8,936) (10,931) (783) $ 1,997 $ 846 $ 12,008 State: Current $ 2,744 $ 1,300 $ 2,265 Deferred (923) (675) (99) $ 1,821 $ 625 $ 2,166 International: Current $ 103,316 $ 97,455 $ 92,199 Deferred (11,547) (8,277) (11,224) $ 91,769 $ 89,178 $ 80,975 Total $ 95,587 $ 90,649 $ 95,149 A reconciliation of the provision for income taxes with the amount computed by applying the statutory federal income tax rate of 21% to income before provision for income taxes is as follows: Years Ended December 31, 2024 2023 2022 Income tax at statutory rate $ 98,651 $ 78,713 $ 70,288 State income taxes, net of federal tax effect 1,439 362 1,475 Excess tax benefits from share-based compensation (11,041) (5,935) (3,306) Deferred tax (benefits) charges, incl. tax rate changes 2,691 (3,512) (2,349) Valuation allowance (14,625) 158 1,486 Legal entity reorganization — 3,630 5,850 Rate differential on earnings of foreign operations 21,357 18,917 19,165 Other items, net (2,885) (1,684) 2,540 Actual income tax provision $ 95,587 $ 90,649 $ 95,149 Effective income tax rate 20.3 % 24.2 % 28.4 % The provision for income tax is favorably impacted by excess tax benefits on deductible share-based compensation. The tax provision for 2024 reflects a $11.0 million benefit from this item compared with a $5.9 million and $3.3 million tax benefit for 2023 and 2022, respectively. The valuation allowance for 2023 and 2022 reflects losses in jurisdictions where we cannot tax effect the loss. During 2024, we changed our previous assessment on the realization of tax losses, and our need for a valuation allowance, in various jurisdictions due to sufficient positive evidence becoming available during the year. Our revised assessment of the realization of tax losses in Luxembourg resulted in a $11.0 million net tax benefit in 2024. Our mix of earnings has an unfavorable tax rate impact since a majority of our pretax income is earned in higher tax jurisdictions. The provision for income taxes for 2023 and 2022 include a $3.6 million and $5.9 million charge, respectively, for taxes related to a legal entity reorganization intended to enhance our dividend and cash management capabilities. Significant deferred tax assets and liabilities as of December 31, 2024 and 2023 are composed of the following temporary differences: 2024 2023 Deferred Tax Assets: Net operating loss carryforwards $ 72,766 $ 49,016 Operating and finance leases 21,712 20,440 Pension liabilities 6,472 13,608 Share-based compensation 3,747 7,326 U.S. state tax credits 5,790 6,110 Vacation and bonus 16,223 16,915 U.S. capitalized research expenditures 41,956 35,563 Inventory 6,094 7,166 Accrued liabilities and other reserves 9,598 9,622 Other 15,575 16,470 Total gross deferred tax assets $ 199,933 $ 182,236 Less valuation allowance (61,134) (48,856) Net deferred tax assets $ 138,799 $ 133,380 Deferred Tax Liabilities: Acquisition related intangibles $ 51,155 $ 57,426 Depreciation and amortization 21,325 25,541 Operating and finance leases 22,672 22,715 Other 8,059 6,988 Total gross deferred tax liabilities $ 103,211 $ 112,670 Net deferred tax assets (liabilities) $ 35,588 $ 20,710 We evaluate the deferred tax assets and record a valuation allowance when it is believed it is more likely than not that the benefit will not be realized. We have established a valuation allowance for $56.9 million of the $72.8 million of tax effected net operating loss carryforwards. These losses are generally in locations that have not produced cumulative three year operating profit. During 2024 we recorded a $29.5 million deferred tax asset for our tax losses in Luxembourg and have established a valuation allowance of $18.5 million related to this asset. Additionally, given our current earnings and anticipated future earnings, we believe there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to support the realization of $7.0 million to $10.0 million of deferred tax assets for which there is currently a corresponding valuation allowance. A valuation allowance of $4.0 million has also been established against the $5.8 million of U.S. state tax credit carryforwards. There is no expiration date on $63.7 million of the tax-effected net operating loss carryforwards and $9.1 million (tax effected) will expire in the years 2025 to 2044. The U.S. state tax credit carryforwards of $5.8 million (tax effected) will expire in the years 2025 to 2039. None of the earnings accumulated outside of the U.S. will be subject to U.S. taxation under the current U.S. federal income tax laws. We maintain our assertion that all other cash and distributable reserves at our non-U.S. affiliates will continue to be indefinitely reinvested, with the exception of earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. We estimate the amount of additional local income tax and withholding tax that would be payable on distributions to be in the range of $15 million to $20 million if earnings accumulated outside the U.S. are repatriated to the U.S. Income Tax Uncertainties We provide a liability for the amount of tax benefits realized from uncertain tax positions. A reconciliation of the beginning and ending amount of income tax uncertainties is as follows: 2024 2023 2022 Balance at January 1 $ 5,942 $ 6,919 $ 7,225 Increases based on tax positions for the current year 300 985 1,433 Increases (Decreases) based on tax positions of prior years 107 (997) (1,616) Settlements (127) (901) (80) Lapse of statute of limitations (430) (64) (43) Balance at December 31 $ 5,792 $ 5,942 $ 6,919 As of December 31, 2024, the total amount of unrecognized tax benefits was $5.8 million, which if recognized, would favorably impact our effective tax rate. We estimate that it is reasonably possible that the liability for uncertain tax positions will decrease by approximately $1.3 million in the next 12 months from the resolution of various uncertain positions as a result of the completion of tax audits, litigation and the expiration of the statute of limitations in various jurisdictions. We recognize interest and penalties related to unrecognized tax benefits as a component of income taxes. As of December 31, 2024, 2023 and 2022, we had approximately $3.6 million, $3.4 million and $4.9 million, respectively, accrued for the payment of interest and penalties, of which approximately $0.2 million, $0.2 million and $0.3 million was recognized in income tax expense for the years ended December 31, 2024, 2023 and 2022, respectively. Aptar or its subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below: Major Tax Tax Years United States — Federal 2021-2024 United States — State 2020-2024 France 2021-2024 Germany 2022-2024 Italy 2018-2024 China 2014-2024

DEBT

DEBT	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
DEBT	DEBT Revolving Credit Facility and Overdrafts At December 31, 2024 and 2023, our revolving credit facility and overdrafts consisted of the following: 2024 2023 Revolving credit facility 3.80% $ 176,035 $ 80,662 Overdrafts — 1,132 $ 176,035 $ 81,794 Aptar has a revolving credit facility (the "revolving credit facility") with a syndicate of banks that provides us with unsecured financing of up to $600 million, which may be increased by up to $300 million more, subject to the satisfaction of certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and could be drawn in various currencies including USD, EUR, GBP, and CHF. The revolving credit facility was set to mature in June 2026, but on July 2, 2024, Aptar entered into a new amended and restated agreement (the "amended revolving credit facility") that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances. As of December 31, 2024, €170.0 million ($176.0 million) was utilized under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2023, Aptar had utilized $36.5 million and €40.0 million ($44.2 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the amended revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. We incurred approximately $9.5 million and $3.9 million in interest and fees related to our credit facility and money market borrowing arrangement during 2024 and 2023, respectively. Average borrowings under the amended revolving credit facility and money market borrowing arrangement were $170.6 million and $60.5 million for 2024 and 2023, respectively. The average annual interest rate on the amended revolving credit facility and money market borrowing arrangement was 5.1% and 5.2% for 2024 and 2023, respectively. Aptar has an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of December 31, 2024 or December 31, 2023. Long-Term Obligations On February 26, 2024, we repaid in full the $100 million 3.49% Senior Unsecured Notes that were due in February 2024. On July 19, 2024, we repaid in full the €200 million 1.17% Senior Unsecured Notes that were due in July 2024. On September 5, 2024, we repaid in full the $50 million 3.4% Senior Unsecured Notes that were due in September 2024. These were repaid using borrowings from our amended revolving credit facility or the Term Loan. On July 19, 2023, we repaid in full the €100 million 0.98% Senior Notes that were due in July 2023. At December 31, 2024 and 2023, our long-term obligations consisted of the following: December 31, 2024 December 31, 2023 Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2030 $ 15,135 $ 14,988 Senior unsecured notes 3.4%, due in 2024 — 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 — 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Term loan 5.8% floating, due in 2027 166,000 — Senior unsecured notes 3.6%, due in 2032, net of discount of $0.7 million 399,258 399,154 Finance Lease Liabilities 23,753 26,478 Unamortized debt issuance costs (3,830) (3,816) $ 850,316 $ 1,057,614 Current maturities of long-term obligations (162,250) (376,426) Total long-term obligations $ 688,066 $ 681,188 The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 8, due annually for the next five years and thereafter are: 2025 $ 158,993 2026 155,457 2027 116,488 2028 88 2029 73 Thereafter 399,294 Covenants Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at December 31, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.08 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 17.43 to 1.00 (1) Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.

LEASE COMMITMENTS

LEASE COMMITMENTS	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
LEASE COMMITMENTS	LEASE COMMITMENTS We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”). The components of lease expense for the years ended December 31, 2024 and 2023 were as follows: Year Ended December 31, 2024 2023 Operating lease cost $ 20,061 $ 20,780 Finance lease cost: Amortization of right-of-use assets $ 6,803 $ 4,662 Interest on lease liabilities 1,192 1,220 Total finance lease cost $ 7,995 $ 5,882 Short-term lease and variable lease costs $ 20,149 $ 20,509 Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,376 $ 21,512 Operating cash flows from finance leases 1,289 1,371 Financing cash flows from finance leases 3,054 3,682 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 33,726 $ 14,514 Finance leases 1,705 2,746 Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 64,213 $ 59,074 Accounts payable, accrued and other liabilities $ 17,015 $ 14,056 Operating lease liabilities 49,716 45,267 Total operating lease liabilities $ 66,731 $ 59,323 Finance Leases Property, plant and equipment, gross $ 50,319 $ 51,846 Accumulated depreciation (20,103) (15,369) Property, plant and equipment, net $ 30,216 $ 36,477 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,563 $ 3,591 Long-term obligations, net of unamortized debt issuance cost 20,190 22,887 Total finance lease liabilities $ 23,753 $ 26,478 Weighted Average Remaining Lease Term (in years) Operating leases 4.7 3.5 Finance leases 4.9 5.3 Weighted Average Discount Rate Operating leases 5.77 % 5.52 % Finance leases 5.12 % 5.05 % Maturities of lease liabilities as of December 31, 2024, were as follows: Operating Finance Year 1 $ 19,758 $ 4,637 Year 2 16,511 3,500 Year 3 12,267 6,683 Year 4 7,387 2,057 Year 5 5,524 7,230 Thereafter 17,649 3,227 Total lease payments 79,096 27,334 Less imputed interest (12,365) (3,581) Total $ 66,731 $ 23,753 As of December 31, 2024, we have additional operating leases that have not yet commenced of $0.9 million and no finance leases that have not yet commenced. These operating leases will commence in 2025 with lease terms of 2 to 4 years.
LEASE COMMITMENTS	LEASE COMMITMENTS We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”). The components of lease expense for the years ended December 31, 2024 and 2023 were as follows: Year Ended December 31, 2024 2023 Operating lease cost $ 20,061 $ 20,780 Finance lease cost: Amortization of right-of-use assets $ 6,803 $ 4,662 Interest on lease liabilities 1,192 1,220 Total finance lease cost $ 7,995 $ 5,882 Short-term lease and variable lease costs $ 20,149 $ 20,509 Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,376 $ 21,512 Operating cash flows from finance leases 1,289 1,371 Financing cash flows from finance leases 3,054 3,682 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 33,726 $ 14,514 Finance leases 1,705 2,746 Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 64,213 $ 59,074 Accounts payable, accrued and other liabilities $ 17,015 $ 14,056 Operating lease liabilities 49,716 45,267 Total operating lease liabilities $ 66,731 $ 59,323 Finance Leases Property, plant and equipment, gross $ 50,319 $ 51,846 Accumulated depreciation (20,103) (15,369) Property, plant and equipment, net $ 30,216 $ 36,477 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,563 $ 3,591 Long-term obligations, net of unamortized debt issuance cost 20,190 22,887 Total finance lease liabilities $ 23,753 $ 26,478 Weighted Average Remaining Lease Term (in years) Operating leases 4.7 3.5 Finance leases 4.9 5.3 Weighted Average Discount Rate Operating leases 5.77 % 5.52 % Finance leases 5.12 % 5.05 % Maturities of lease liabilities as of December 31, 2024, were as follows: Operating Finance Year 1 $ 19,758 $ 4,637 Year 2 16,511 3,500 Year 3 12,267 6,683 Year 4 7,387 2,057 Year 5 5,524 7,230 Thereafter 17,649 3,227 Total lease payments 79,096 27,334 Less imputed interest (12,365) (3,581) Total $ 66,731 $ 23,753 As of December 31, 2024, we have additional operating leases that have not yet commenced of $0.9 million and no finance leases that have not yet commenced. These operating leases will commence in 2025 with lease terms of 2 to 4 years.

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANS We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion. Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date. The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans. Domestic Plans Foreign Plans 2024 2023 2024 2023 Change in benefit obligation: Benefit obligation at beginning of year $ 186,013 $ 163,872 $ 104,757 $ 93,999 Service cost 9,462 9,638 6,492 5,915 Interest cost 8,968 8,631 3,488 3,642 Plan Amendment — — (17) — Curtailment/Settlement — — (1,385) (606) Prior service cost — — — (1,134) Actuarial (gain) loss (18,156) 13,989 1,370 6,906 Benefits paid (11,093) (10,117) (3,776) (6,788) Foreign currency translation adjustment (loss) gain — — (6,733) 2,823 Benefit obligation at end of year $ 175,194 $ 186,013 $ 104,196 $ 104,757 Domestic Plans Foreign Plans 2024 2023 2024 2023 Change in plan assets: Fair value of plan assets at beginning of year $ 173,735 $ 162,151 $ 72,434 $ 72,523 Actual return on plan assets 17,624 21,207 3,605 3,978 Employer contribution 495 494 3,580 477 Benefits paid (11,093) (10,117) (3,776) (6,788) Foreign currency translation adjustment — — (4,593) 2,244 Fair value of plan assets at end of year $ 180,761 $ 173,735 $ 71,250 $ 72,434 Funded status at end of year $ 5,567 $ (12,278) $ (32,946) $ (32,323) The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Non-current assets $ 19,739 $ 2,528 $ 3,648 $ 1,664 Current liabilities (546) (530) (46) (32) Non-current liabilities (13,626) (14,276) (36,548) (33,955) $ 5,567 $ (12,278) $ (32,946) $ (32,323) The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Net actuarial (gain) loss $ (21,495) $ 1,823 $ 16,201 $ 15,661 Net prior service cost — — (531) (162) Tax effects 6,713 1,029 (6,413) (6,463) $ (14,782) $ 2,852 $ 9,257 $ 9,036 Changes in benefit obligations and plan assets recognized in other comprehensive income in 2024, 2023 and 2022 are as follows: Domestic Plans 2024 2023 2022 Current year actuarial gain (loss) $ 23,318 $ (5,161) $ 54,295 Amortization of net loss — — 6,670 $ 23,318 $ (5,161) $ 60,965 Foreign Plans 2024 2023 2022 Current year actuarial (loss) gain $ (47) $ (5,315) $ 19,181 Current year prior service cost 20 1,135 (818) Transfer actuarial gain (loss) (694) 124 17 Amortization of net loss 201 914 1,688 Amortization of prior service cost 349 177 177 $ (171) $ (2,966) $ 20,245 Components of net periodic benefit cost: Domestic Plans 2024 2023 2022 Service cost $ 9,462 $ 9,638 $ 15,784 Interest cost 8,968 8,631 6,970 Expected return on plan assets (12,463) (12,378) (12,912) Amortization of net loss — — 6,670 Net periodic benefit cost $ 5,967 $ 5,891 $ 16,512 Foreign Plans 2024 2023 2022 Service cost $ 6,492 $ 5,915 $ 7,547 Interest cost 3,488 3,642 1,388 Expected return on plan assets (2,243) (2,340) (2,728) Amortization of net loss 201 914 1,688 Amortization of prior service cost 349 177 177 Net periodic benefit cost $ 8,287 $ 8,308 $ 8,072 Curtailment (2,205) (1) (24) Total Net periodic benefit cost $ 6,082 $ 8,307 $ 8,048 The accumulated benefit obligation (“ABO”) for our domestic defined benefit pension plans was $163.4 million and $171.6 million at 2024 and 2023, respectively. The ABO for our foreign defined benefit pension plans was $80.2 million and $80.1 million at December 31, 2024 and 2023, respectively. The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Projected benefit obligation $ 14,172 $ 14,806 $ 77,645 $ 56,881 Accumulated benefit obligation 12,412 12,156 54,460 40,312 Fair value of plan assets — — 41,238 29,372 The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Projected benefit obligation $ 14,172 $ 14,806 $ 81,273 $ 81,534 Accumulated benefit obligation 12,412 12,156 57,494 56,969 Fair value of plan assets — — 44,676 47,544 Assumptions: Domestic Plans Foreign Plans 2024 2023 2022 2024 2023 2022 Weighted-average assumptions used to determine benefit obligations at December 31: Discount rate 5.60 % 4.95 % 5.15 % 3.33 % 3.20 % 3.69 % Rate of compensation increase 3.24 % 3.24 % 3.20 % 3.21 % 3.20 % 3.21 % Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31: Discount rate 4.95 % 5.15 % 2.75 % 3.32 % 3.69 % 1.20 % Expected long-term return on plan assets 7.00 % 7.00 % 7.00 % 3.22 % 3.23 % 3.53 % Rate of compensation increase 3.24 % 3.20 % 3.17 % 3.21 % 3.20 % 3.20 % We develop the expected long-term rate of return assumptions based on historical experience and by evaluating input from the plans’ asset managers, including the managers’ review of asset class return expectations and benchmarks, economic indicators and long-term inflation assumptions. In order to determine the 2025 net periodic benefit cost, we expect to use the December 31, 2024 discount rates, December 31, 2024 rates of compensation increase assumptions and the same assumed long-term returns on domestic and foreign plan assets used for the 2024 net periodic benefit cost. Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2024 and 2023 by asset category are as follows: Plan Assets: Domestic Plans Assets at December 31, Foreign Plans Assets at December 31, 2024 2023 2024 2023 Equity securities 50 % 48 % 3 % 3 % Fixed income securities 25 % 27 % 1 % 1 % Corporate debt securities — — 2 % 1 % Infrastructure 8 % 8 % — — Hedge funds 11 % 11 % — — Money market 2 % 1 % — % 1 % Investment Funds — — 94 % 94 % Real estate 4 % 5 % — — Total 100 % 100 % 100 % 100 % Our investment strategy for our domestic and foreign pension plans is to maximize the long-term rate of return on plan assets within an acceptable level of risk. The investment policy strives to have assets sufficiently diversified so that adverse or unexpected results from one security type will not have an unduly detrimental impact on the entire portfolio and accordingly, establishes a target allocation for each asset category within the portfolio. The domestic plan asset allocation is reviewed on a quarterly basis and the foreign plan asset allocation is reviewed annually. Rebalancing occurs as needed to comply with the investment strategy. The domestic plan target allocation for 2025 is 63% equity securities and 37% fixed income securities and infrastructure. The foreign plan target allocation for 2025 is 100% investment funds. Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. Domestic Fair Value Measurement at December 31, 2024 Foreign Fair Value Measurement at December 31, 2024 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 3,054 $ 3,054 $ — $ — $ 275 $ 275 $ — $ — USD — 3,054 — — — — — — EUR — — — — — 269 — — Others — — — — — 6 — — Equity Securities (a) $ 78,234 $ 78,234 $ — $ — $ 1,873 $ 1,873 $ — $ — U.S. Large Cap Equities — 45,294 — — — — — — U.S. Small Cap Equities — 10,363 — — — — — — International Equities — 22,577 — — — 1,873 — — Fixed Income (a)(b) $ 28,526 $ 28,526 $ — $ — $ 562 $ 562 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,213 $ 1,213 $ — $ — Euro Corporate Bonds (a) — — — — — 1,213 — — Investment Funds $ — $ — $ — $ — $ 67,327 $ 24,377 $ 42,950 $ — Mutual Funds in Equities (a) — — — — — 5,781 — — Mutual Funds in Bonds (a) — — — — — 14,634 — — Mutual Funds Diversified (a)(b) — — — — — 3,962 42,950 — Total Investments in Fair Value Hierarchy $ 109,814 $ 109,814 $ — $ — $ 71,250 $ 28,300 $ 42,950 $ — Investments at Net Asset Value per Share 70,947 — — — — — — — Total Investments $ 180,761 $ 109,814 $ — $ — $ 71,250 $ 28,300 $ 42,950 $ — Domestic Fair Value Measurement at December 31, 2023 Foreign Fair Value Measurement at December 31, 2023 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,949 $ 1,949 $ — $ — $ 514 $ 514 $ — $ — USD — 1,949 — — — — — — EUR — — — — — 506 — — Others — — — — — 8 — — Equity Securities (a) $ 73,483 $ 73,483 $ — $ — $ 2,106 $ 2,106 $ — $ — U.S. Large Cap Equities — 43,156 — — — — — — U.S. Small Cap Equities — 8,864 — — — — — — International Equities — 21,463 — — — 2,106 — — Fixed Income (a)(b) $ 29,171 $ 29,171 $ — $ — $ 831 $ 831 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,231 $ 1,231 $ — $ — Euro Corporate Bonds (a) — — — — — 1,231 — — Investment Funds $ — $ — $ — $ — $ 67,752 $ 23,513 $ 44,239 $ — Mutual Funds in Equities (a) — — — — — 5,411 — — Mutual Funds in Bonds (a) — — — — — 17,256 — — Mutual Funds Diversified (a)(b) — — — — — 846 44,239 — Total Investments in Fair Value Hierarchy $ 104,603 $ 104,603 $ — $ — $ 72,434 $ 28,195 $ 44,239 $ — Investments at Net Asset Value per Share 69,132 — — — — — — — Total Investments $ 173,735 $ 104,603 $ — $ — $ 72,434 $ 28,195 $ 44,239 $ — (a) Based on third party quotation from financial institution. (b) Based on observable market transactions. Contributions Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by ERISA. We contributed $0.5 million SERP plans in 2024 and although we have no minimum funding requirement, we plan to contribute approximately $10.0 million and $0.5 million to pay our domestic defined benefit plans and SERP plans, respectively, in 2025. Contributions to fund pension costs accrued under our foreign plans are made in accordance with local laws or at our discretion. We contributed approximately $3.6 million to our foreign defined benefit plan in 2024 and expect to contribute approximately $0.8 million in 2025. Estimated Future Benefit Payments As of December 31, 2024, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next 10 years: Domestic Plans Foreign Plans 2025 $ 10,191 $ 5,557 2026 10,932 3,027 2027 10,764 4,305 2028 11,915 4,874 2029 13,139 6,066 2030 - 2034 72,913 39,041 Other Plans We have a non-qualified supplemental pension plan for domestic employees which provides for pension amounts that would have been payable from our principal domestic pension plan if it were not for limitations imposed by income tax regulations. The liability for this plan, which is not funded, was $14.2 million and $14.8 million at December 31, 2024 and 2023, respectively. This amount is included in the liability for domestic plans shown above. We have a defined contribution 401(k) employee savings plan ("401(k) plan") available to substantially all domestic employees. Company matching contributions are made in cash up to a maximum of 3% of the participating employee’s salary subject to income tax regulations. For each of the years ended December 31, 2024, 2023 and 2022, total contributions made to these plans were approximately $5.0 million, $5.0 million and $5.0 million, respectively. As discussed above, domestic employees hired after December 31, 2020 will no longer be eligible for the pension plans and will instead receive an annual Aptar Retirement Savings Account contribution of 5% of their eligible earnings in the 401(k) plan. For the years ended December 31, 2024, 2023 and 2022, total contributions for these eligible employees was approximately $3.3 million, $2.7 million and $2.0 million, respectively. We have several foreign defined contribution plans, which require us to contribute a percentage of the participating employee’s salary according to local regulations. For each of the years ended December 31, 2024, 2023 and 2022, total contributions made to these plans were approximately $3.0 million, $3.1 million and $2.9 million, respectively. We have no additional postretirement or postemployment benefit plans.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)	12 Months Ended
	Dec. 31, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Changes in Accumulated Other Comprehensive Income/(Loss) by Component: Foreign Defined Benefit Derivatives Total Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (79,240) 54,149 (6,666) (31,757) Amounts reclassified from accumulated other comprehensive income (loss) — 6,386 46 6,432 Net current-period other comprehensive (loss) income (79,240) 60,535 (6,620) (25,325) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive (loss) income before reclassifications 48,658 (6,711) (10,086) 31,861 Amounts reclassified from accumulated other comprehensive income — 771 — 771 Net current-period other comprehensive (loss) income 48,658 (5,940) (10,086) 32,632 Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (145,967) 17,043 7,813 (121,111) Amounts reclassified from accumulated other comprehensive income — 370 — 370 Net current-period other comprehensive (loss) income (145,967) 17,413 7,813 (120,741) Balance - December 31, 2024 $ (426,049) $ 5,522 $ (8,948) $ (429,475) Reclassifications Out of Accumulated Other Comprehensive Income/(Loss): Details about Accumulated Other Amount Reclassified from Affected Line in the Statement Year Ended December 31, 2024 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 201 $ 914 $ 8,358 (1) Amortization of prior service cost 349 177 177 (1) 550 1,091 8,535 Total before tax (180) (320) (2,149) Tax benefit $ 370 $ 771 $ 6,386 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ — $ (171) Interest Expense Changes in cross currency swap: foreign exchange component — — 217 Miscellaneous, net $ — $ — $ 46 Net of tax Total reclassifications for the period $ 370 $ 771 $ 6,432 (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Consolidated Balance Sheets (See Note 12 – Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Consolidated Statements of Cash Flows. Net Investment Hedge A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% EUR debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. As of December 31, 2024, the fair value of the cross currency swap was a $11.9 million liability. The swap agreement will mature on September 15, 2029. Other As of December 31, 2024, we have recorded the fair value of foreign currency forward exchange contracts of $0.6 million in prepaid and other and $0.6 million in accounts payable, accrued and other liabilities in the Consolidated Balance Sheets. All forward exchange contracts outstanding as of December 31, 2024 had an aggregate notional contract amount of $69.9 million. Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023 December 31, 2024 December 31, 2023 Balance Sheet Derivatives Derivatives Derivatives Derivatives Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 572 $ — $ 386 $ — $ 572 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 622 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 11,851 — 22,199 — $ 11,851 $ 622 $ 22,199 $ 221 (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component. The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Fiscal Years Ended December 31, 2024 and December 31, 2023 Derivatives in Cash Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount 2024 2023 2024 2023 Cross currency swap contract: Foreign exchange component $ 7,813 $ (10,086) Miscellaneous, net $ — $ — $ 3,265 $ 7,813 $ (10,086) $ — $ — The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2024 and December 31, 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (190) $ (668) $ (190) $ (668) Gross Amounts Net Amounts Gross Amounts not Offset Gross Financial Cash Collateral Net Description December 31, 2024 Derivative Assets $ 572 $ — $ 572 $ — $ — $ 572 Total Assets $ 572 $ — $ 572 $ — $ — $ 572 Derivative Liabilities $ 12,473 $ — $ 12,473 $ — $ — $ 12,473 Total Liabilities $ 12,473 $ — $ 12,473 $ — $ — $ 12,473 December 31, 2023 Derivative Assets $ 386 $ — $ 386 $ — $ — $ 386 Total Assets $ 386 $ — $ 386 $ — $ — $ 386 Derivative Liabilities $ 22,420 $ — $ 22,420 $ — $ — $ 22,420 Total Liabilities $ 22,420 $ — $ 22,420 $ — $ — $ 22,420

FAIR VALUE

FAIR VALUE	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of December 31, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 2,986 $ 2,986 $ — $ — Foreign exchange contracts (2) 572 — 572 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 9,208 $ 2,986 $ 572 $ 5,650 Liabilities Foreign exchange contracts (2) $ 622 $ — $ 622 $ — Cross currency swap contract (2) 11,851 — 11,851 — Total liabilities at fair value $ 12,473 $ — $ 12,473 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Consolidated Balance Sheets. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $0.6 billion as of December 31, 2024 and December 31, 2023, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. We have various purchase commitments for raw materials, supplies, and property and equipment obtained in the normal course of business. As of December 31, 2024, we have unconditional purchase commitments of approximately $46.1 million of which the majority relate to open purchase orders for fixed assets over the next four years, for which no liabilities have been recorded. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of December 31, 2024. A fire caused damage to our facility in Annecy, France in June 2016. We were insured for the damages caused by the fire, including business interruption insurance. In 2022, we filed a lawsuit against the insurance company to recover a part of our claim. We reached a settlement with the insurance company during the fourth quarter of 2023 for $6.6 million, which is recorded in Miscellaneous income (expense), net in our Consolidated Statements of Income. We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $12 million in principal and $15 million to $16 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the probability of settlement and the timing of our appeal, no liability is recorded as of December 31, 2024. We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On October 10, 2024, we announced a share repurchase authorization of up to $500 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. In 2024, 2023 and 2022, we repurchased approximately 433 thousand, 399 thousand and 860 thousand shares, respectively, of our outstanding common stock at a total cost of $68.6 million, $47.6 million and $92.1 million, respectively. As of December 31, 2024, there was $462.7 million of authorized share repurchases available to us.

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Dec. 31, 2024
CAPITAL STOCK
CAPITAL STOCK	CAPITAL STOCK We have 199 million authorized shares of common stock. The number of shares of common stock and treasury stock and the share activity were as follows: Common Shares Treasury Shares 2024 2023 2022 2024 2023 2022 Balance at the beginning of the year 71,679,658 70,848,810 70,370,812 5,775,295 5,555,027 4,852,709 Employee option exercises 629,541 679,878 301,463 (192,123) (178,326) (157,682) Director option exercises 6,500 — — — — — Restricted stock vestings 150,849 150,970 176,535 — — — Common stock repurchases — — — 432,600 398,594 860,000 Balance at the end of the year 72,466,548 71,679,658 70,848,810 6,015,772 5,775,295 5,555,027 The cash dividends paid on the common stock for the years ended December 31, 2024, 2023 and 2022 aggregated $114.1 million, $103.7 million and $99.5 million, respectively.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company's 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest based on our return on invested capital ("ROIC"). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return (“TSR”) modifier. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Year Ended December 31, 2024 2023 (1) 2022 Fair value per stock award $ 145.79 $ 116.17 $ 141.95 Grant date stock price $ 141.00 $ 111.38 $ 114.52 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % 20.20 % Expected average volatility of peer companies 34.80 % 39.70 % 41.70 % Correlation assumption 30.70 % 33.30 % 41.20 % Risk-free interest rate 4.51 % 3.83 % 2.04 % Dividend yield assumption 1.16 % 1.36 % 1.33 % (1) The 2023 award inputs and assumptions are related to PSU-ROIC awards with a TSR modifier. A summary of RSU activity as of December 31, 2024, and changes during the period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 130,098 138.24 129,614 145.79 Vested (184,631) 119.11 (97,686) 162.24 Forfeited (4,096) 119.31 (33,085) 142.78 Nonvested at December 31, 2024 277,245 $ 123.28 513,226 $ 127.17 Included in the December 31, 2024 time-based RSU activity are 10,208 units granted to non-employee directors and 11,508 units vested related to non-employee directors. Year Ended December 31, 2024 2023 2022 Compensation expense $ 40,581 $ 37,015 $ 40,937 Fair value of units vested 36,313 29,100 32,013 Intrinsic value of units vested 40,083 33,914 33,024 The actual tax benefit realized for the tax deduction from RSUs was approximately $7.6 million, $5.9 million and $8.0 million for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was $44.9 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted average period of 1.8 years. Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were reinstituted for employees in 2023 and valued based on the Black-Scholes model and generally vest ratably over three years and expire 10 years after grant. The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $36.07 per share for all employees during 2024. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all other employees, respectively, during 2023. In 2023, Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. The exercise price of the options granted in 2024 was $141.00. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Year Ended December 31, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0 A summary of option activity under our stock plans as of December 31, 2024, and changes during the period then ended is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (750,771) 71.62 (19,000) 66.59 Forfeited or expired (18,511) 87.66 — — Outstanding at December 31, 2024 1,663,307 $ 93.69 — $ — Exercisable at December 31, 2024 1,211,208 $ 80.20 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at December 31, 2024 4.2 0.0 Exercisable at December 31, 2024 2.5 0.0 Aggregate Intrinsic Value: Outstanding at December 31, 2024 $ 105,470 $ — Exercisable at December 31, 2024 $ 93,145 $ — Intrinsic Value of Options Exercised During the Years Ended: December 31, 2024 $ 57,259 $ 1,394 December 31, 2023 $ 38,706 $ 1,978 December 31, 2022 $ 20,608 $ — Year Ended December 31, 2024 2023 2022 Compensation expense (included in SG&A) $ 6,381 $ 3,929 $ — Compensation expense (included in Cost of sales) 688 349 — Compensation expense, Total $ 7,069 $ 4,278 $ — Compensation expense, net of tax 6,880 4,278 — Grant date fair value of options vested 2,320 2,663 — The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises was approximately $54.8 million, $54.0 million and $28.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $13.2 million, $9.1 million and $4.4 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was $4.5 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 1.8 years.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2024, 2023 and 2022 are as follows: Income Shares Per Share For the Year Ended December 31, 2024 Basic EPS Income available to common stockholders $ 374,541 66,334 $ 5.65 Effect of Dilutive Securities Stock options 765 Restricted stock 592 Diluted EPS Income available to common stockholders $ 374,541 67,691 $ 5.53 For the Year Ended December 31, 2023 Basic EPS Income available to common stockholders $ 284,487 65,616 $ 4.34 Effect of Dilutive Securities Stock options 874 Restricted stock 415 Diluted EPS Income available to common stockholders $ 284,487 66,905 $ 4.25 For the Year Ended December 31, 2022 Basic EPS Income available to common stockholders $ 239,288 65,402 $ 3.66 Effect of Dilutive Securities Stock options 978 Restricted stock 339 Diluted EPS Income available to common stockholders $ 239,288 66,719 $ 3.59

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Effective January 1, 2023, we combined all of our closures technologies into one segment, and realigned and renamed two of our three segments. Our reporting segments became: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets. The Aptar Closures business serves multiple markets, including food, beverage, personal care, home care, beauty and healthcare. Aptar's food protection business and our elastomeric flow-control technology business continue to report through the Aptar Closures segment. The realignment brings us closer to how our customers are structured and operate their business. At the same time, we simplified and focused our Beauty segment to better leverage our complex spray and dispensing solutions for prestige and mass brands in the beauty, personal care and home care markets. The segment realignment had no impact on our Consolidated Statements of Income, Balance Sheets, and Cash Flows. Segment financial information for the prior periods has been recast to conform to the current presentation. The accounting policies of the segments are the same as those described in Note 1 – Summary of Significant Accounting Policies. We adopted ASU 2023-07, Improvement to Reportable Segment Disclosures which requires enhanced segment disclosure. Our chief operating decision maker, ("CODM") is our President and Chief Executive Officer, Stephan Tanda. Our CODM is provided operating reports from each of our reportable segments which include or can easily derive significant segment expenses identified as selling, research & development and administrative expenses and cost of sales by segment. Additionally, the other segment items is primarily comprised of foreign currency gains or losses from operations and other non-operating activity. Our CODM evaluates performance of our reporting segments and allocates resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA provides useful information regarding performance of each segment as it reflects profitability and performance of each segment on a consistent and comparable basis, and our CODM considers budget-to-actual variances on a monthly basis when making decisions supporting capital resource allocation, including in connection with development, acquisition and disposition activities in each segment. Financial information regarding our reporting segments is shown below: In thousands Year Ended December 31, 2024 2023 2022 Total Sales: Aptar Pharma $ 1,644,012 $ 1,521,837 $ 1,372,449 Aptar Beauty 1,252,904 1,297,477 1,246,018 Aptar Closures 721,564 706,847 748,055 Total Sales $ 3,618,480 $ 3,526,161 $ 3,366,522 Less: Intersegment Sales: Aptar Pharma $ 860 $ 844 $ 11,193 Aptar Beauty 27,174 29,780 23,483 Aptar Closures 7,556 8,087 9,597 Total Intersegment Sales $ 35,590 $ 38,711 $ 44,273 Net Sales: Aptar Pharma $ 1,643,152 $ 1,520,993 $ 1,361,256 Aptar Beauty 1,225,730 1,267,697 1,222,535 Aptar Closures 714,008 698,760 738,458 Net Sales $ 3,582,890 $ 3,487,450 $ 3,322,249 Less: Cost of Sales (exclusive of depreciation and amortization): Aptar Pharma 834,595 797,542 709,873 Aptar Beauty 884,433 922,223 891,619 Aptar Closures 511,409 507,866 560,300 Selling, Research & Development and Administrative: Aptar Pharma 241,357 221,808 211,101 Aptar Beauty 183,903 192,831 180,910 Aptar Closures 89,913 87,930 92,697 Other Segment Items: Aptar Pharma (1,171) (990) (1,340) Aptar Beauty (2,515) (11,073) (1,881) Aptar Closures (1,456) (729) (648) Adjusted EBITDA (1): Aptar Pharma $ 568,371 $ 502,633 $ 441,622 Aptar Beauty 159,909 163,716 151,887 Aptar Closures 114,142 103,693 86,109 Adjusted EBITDA for Reportable Segments $ 842,422 $ 770,042 $ 679,618 Corporate & Other, unallocated (67,498) (62,320) (62,930) Acquisition-related costs (2) (140) (480) (231) Restructuring Initiatives (3) (13,002) (45,004) (6,597) Curtailment gain related to restructuring initiatives (4) 1,851 — — Net unrealized investment gain (loss) (5) 1,713 (2,775) (3,323) Depreciation and amortization (263,784) (248,593) (233,706) Interest Expense (43,898) (40,418) (40,827) Interest Income 12,101 4,373 2,700 Income before Income Taxes $ 469,765 $ 374,825 $ 334,704 In thousands Year Ended December 31, 2024 2023 2022 Depreciation and Amortization: Aptar Pharma $ 120,429 $ 109,366 $ 94,396 Aptar Beauty 82,931 83,399 80,498 Aptar Closures 57,326 52,095 52,866 Depreciation and Amortization for Reportable Segments 260,686 244,860 227,760 Corporate & Other 3,098 3,733 5,946 Depreciation and Amortization $ 263,784 $ 248,593 $ 233,706 Capital Expenditures: Aptar Pharma $ 148,261 $ 196,083 $ 164,396 Aptar Beauty 64,571 83,872 74,203 Aptar Closures 45,766 52,160 44,223 Capital Expenditures for Reportable Segments 258,598 332,115 282,822 Corporate & Other 23,630 14,729 29,491 Transfer of Corporate Expenditures (6) (5,747) (34,502) (1,886) Capital Expenditures $ 276,481 $ 312,342 $ 310,427 Total Assets: Aptar Pharma $ 2,057,586 $ 2,111,779 $ 1,872,843 Aptar Beauty 1,392,491 1,412,203 1,398,813 Aptar Closures 746,127 765,930 779,654 Total Assets for Reportable Segments 4,196,204 4,289,912 4,051,310 Corporate & Other 236,074 161,978 152,148 Total Assets $ 4,432,278 $ 4,451,890 $ 4,203,458 (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 19 - Acquisitions and Note 20 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the years ended December 31, 2024, 2023 and 2022 as follows (see Note 21 – Restructuring Initiatives for further details): In thousands Year Ended December 31, 2024 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 13,019 $ 45,445 $ 6,224 Prior year initiatives (17) (441) 373 Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597 Restructuring Initiatives by Segment: Aptar Pharma $ 589 $ 4,852 $ — Aptar Beauty 8,041 20,683 5,539 Aptar Closures 3,835 17,927 1,058 Corporate & Other 537 1,542 — Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597 (4) The curtailment gain is included in the line miscellaneous income (expense), net (5) Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 20 – Investment in Equity Securities for further details). (6) The transfer of corporate expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level. The increase in 2023 relates to a project build in Suzhou, China. Geographic Information The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2024, 2023 and 2022: 2024 2023 2022 Net Sales to Unaffiliated Customers (1): United States $ 1,037,968 $ 949,248 $ 972,920 Europe: France 499,795 541,333 487,650 Germany 169,891 160,812 163,277 Italy 180,101 200,817 149,725 Spain 171,779 175,101 149,987 Other Europe 748,302 727,662 665,537 Total Europe 1,769,868 1,805,725 1,616,176 China 155,502 146,026 177,855 Other Foreign Countries 619,552 586,451 555,298 Total $ 3,582,890 $ 3,487,450 $ 3,322,249 Property, Plant and Equipment, Net United States $ 349,255 $ 357,729 $ 346,382 Europe: France 527,570 550,738 482,091 Germany 229,637 225,860 194,898 Italy 44,087 42,240 42,522 Other Europe 66,546 63,864 53,317 Total Europe 867,840 882,702 772,828 China 105,613 112,017 98,469 Other Foreign Countries 124,442 125,615 125,985 Total $ 1,447,150 $ 1,478,063 $ 1,343,664 (1) Sales are attributed to countries based upon shipped to location. No single customer or group of affiliated customers represents greater than 4% of our net sales in 2024 and 5% of our net sales in 2023 or 2022.

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations On August 1, 2023, we paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition. No further liability remains outstanding for this acquisition. On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition. Also on March 1, 2023, we completed the acquisition of 80% of the equity interests in Gulf Closures W.L.L. ("Gulf Closures"). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition. For the year ended December 31, 2023, we recognized $0.3 million in transaction costs related to the acquisitions of iD SCENT and Gulf Closures. These costs are reflected in the selling, research & development and administration section of the Consolidated Statements of Income and within acquisition-related costs as disclosed in Note 18 – Segment Information. Pro forma 2023 reported results of operations for the acquisitions have not been presented as the effects of these business combinations individually and in aggregate were not material to the consolidated results of operations. Goodwill in the amount of $3.8 million was recorded related to the 2023 acquisitions, of which $3.7 million is included in the Aptar Beauty segment and $0.1 million is included in the Aptar Closures segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill acquired in our 2023 acquisitions has expanded our portfolio of fragrance sampling solutions, and has expanded our market opportunities and strengthens our presence in the Middle East region. Goodwill will not be amortized, but will be tested for impairment at least annually. For 2024 and 2023 acquisitions, no goodwill will be deductible for tax purposes.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: December 31, 2024 December 31, 2023 Equity Method Investments Goldrain $ 96,667 $ — BTY 32,047 33,090 Sonmol 4,712 4,751 Desotec GmbH 948 905 Other Investments PureCycle 2,986 1,106 YAT 5,206 5,352 Loop 2,894 2,894 Others 809 1,105 $ 146,269 $ 49,203 Equity Method Investments Goldrain On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products. Additionally, we noted an initial basis difference between our investment in the business and the amount recorded in Goldrain's equity of $82.7 million including equity method goodwill that will not be amortized. The future amortizable basis difference of $14.7 million as of December 31, 2024 was comprised of intangible assets which are being amortized on a straight line basis over a weighted average useful life of 11.8 years. BTY On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32 million. Additionally, we noted an initial basis difference between our investment in the business and the amount recorded in BTY's equity of $21.7 million including equity method goodwill that will not be amortized. The future amortizable basis difference of $3.5 million as of December 31, 2024 was comprised of intangible assets which are being amortized on a straight line basis over a weighted average useful life of 13.9 years. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the years ended December 31, 2024, 2023 and 2022, Aptar had purchases of $11.4 million, $14.3 million and $11.4 million, respectively, from BTY. As of December 31, 2024 and 2023, approximately $2.5 million and $1.8 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Consolidated Balance Sheets. Sonmol On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker "PCT". At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Consolidated Statements of Income. Our remaining investment is subject to lockup conditions that will be released upon PCT's Ironton facility becoming operational and certified by Leidos, as such the duration of the lockup is unknown. We have sold the following PCT shares related to the PureCycle investment for the years ended December 31, 2023 and 2022: Shares Sold Proceeds Realized Gain 2022 157,600 $ 1,599 $ 1,213 2023 510,449 $ 5,604 $ 4,188 No shares were sold during 2024 related to PCT. On April 26, 2024, we received $0.2 million of equity from PureCycle in exchange for our resource dedication for technological partnership and support. For the years ended December 31, 2024, 2023 and 2022 we recorded the following net investment gain or loss on our investment in PureCycle: 2024 2023 2022 Net investment gain (loss) $ 1,713 $ 1,413 $ (2,110) On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the year ended December 31, 2024 related to these investments.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES For the years ended December 31, 2024, 2023 and 2022, we recognized $13.0 million, $45.4 million and $6.2 million, respectively, of restructuring costs related to our initiative to better leverage our fixed cost base through growth and cost reduction measures. The cumulative expense incurred as of December 31, 2024 was $64.7 million. As of December 31, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Year Ended December 31, 2024 Cash Paid Interest and Ending Reserve at December 31, 2024 Employee severance $ 27,078 $ 6,562 $ (23,791) $ (688) $ 9,161 Professional fees and other costs 2,810 6,457 (8,559) 88 796 Totals $ 29,888 $ 13,019 $ (32,350) $ (600) $ 9,957 As of December 31, 2023, we recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2022 Net Charges for the Year Ended December 31, 2023 Cash Paid Interest and Ending Reserve at December 31, 2023 Employee severance $ 4,993 $ 37,167 $ (12,608) $ (2,474) $ 27,078 Professional fees and other costs — 8,278 (5,486) 18 2,810 Totals $ 4,993 $ 45,445 $ (18,094) $ (2,456) $ 29,888

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	AptarGroup, Inc SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS For the years ended December 31, 2024, 2023 and 2022 Dollars in thousands Balance at Charged to Charged Deductions from Reserve Balance 2024 CECL (a) $ 16,217 $ 1,016 $ — $ (1,448) $ 15,785 Deferred tax valuation allowance (b) 48,856 1,739 26,903 (16,364) 61,134 2023 CECL (a) $ 9,519 $ 8,077 $ 12 $ (1,391) $ 16,217 Deferred tax valuation allowance 46,239 1,498 2,495 (1,376) 48,856 2022 CECL (a) $ 7,374 $ 3,213 $ — $ (1,068) $ 9,519 Deferred tax valuation allowance 47,149 3,754 380 (5,044) 46,239 (a) The deductions from reserve column represents the write-off of accounts considered uncollectible, net of recoveries and foreign currency impact adjustments. (b) The 2024 increase to the deferred tax valuation allowance in the charged to other accounts column primarily relates to the establishment of a $29.5 million deferred tax valuation allowance for deferred tax assets established to reflect prior period tax losses not previously expected to be realized that were not recognized on the Balance Sheet. As of December 31, 2024, management expects $11.0 million of these losses to be realizable in future periods, which is reflected in the deductions from the reserve column.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 374,541	$ 284,487	$ 239,288

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Increased global cybersecurity threats and sophisticated, targeted computer crime could pose a risk to our operations. Aptar has strategically integrated cybersecurity risk management into a broader enterprise-wide risk management framework, and consists of administrative, operational, organizational, physical, and technical processes that we believe are appropriate to the scope and nature of our business. We believe this integrated approach allows cybersecurity considerations to be an integral part of our decision-making processes. Our risk management team works closely with our Information Security Department to continuously evaluate and address cybersecurity risks in alignment with our business and operational needs. Our cybersecurity strategy focuses on continued strengthening of our security posture, improvement of security operational efficiencies, and preparedness for evolving business and technology needs including the detection, analysis, and response to known, anticipated or unexpected cybersecurity threats, management of material risks related to cybersecurity threats and resilience against cybersecurity incidents. We regularly assess potential threats and make investments seeking to reduce the risk of these threats against our critical information and assets by implementing a broad set of security measures, including comprehensive monitoring of our networks and systems, rapid detection and response, and threat management capabilities. For example, we scan our systems for vulnerabilities and annually engage external experts, including cybersecurity assessors, consultants, and auditors in evaluating and testing our cybersecurity systems. The results of such assessments and reviews are reported to our Information Security Department and Audit Committee of the Board of Directors (the "Audit Committee"), and then we consider adjustments to our cybersecurity processes and practices as appropriate based on the information provided by the third-party assessments and reviews. Security and data privacy awareness and training is provided to new employees and annually for current Aptar employees, is designed to educate employees on recognizing information security and cybersecurity concerns, how they can help protect the organization and how to inform the cybersecurity team of potential incidents. In addition, Aptar implements stringent processes to oversee and manage risks associated with our third-party providers. As set forth in our Sustainable Purchasing Charter, third-party providers are expected to, among other things, protect personal data and implement security and protection measures in relation thereto. We conduct security assessments of third-party providers before engagement and monitor their compliance with our cybersecurity standards on an ongoing basis. The monitoring includes periodic and ongoing assessments by our Information Security Department. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties. In addition, we maintain cybersecurity insurance as part of our overall insurance portfolio.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Aptar has strategically integrated cybersecurity risk management into a broader enterprise-wide risk management framework, and consists of administrative, operational, organizational, physical, and technical processes that we believe are appropriate to the scope and nature of our business. We believe this integrated approach allows cybersecurity considerations to be an integral part of our decision-making processes.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Management reports to the Audit Committee on a quarterly basis regarding our information security programs. As part of its oversight responsibilities, the Audit Committee regularly discusses and reviews with management, among other items, Aptar’s compliance and cybersecurity programs. We also periodically test our systems for vulnerabilities and regularly engage third parties to conduct evaluations of our security controls whether through penetration testing, independent audit or consulting on best practices to address new challenges. An independent review of our cybersecurity program has been assessed against the National Institute of Standards and Technology (NIST) cybersecurity framework. In addition, we maintain cybersecurity insurance as part of our overall insurance portfolio. Our Information Security Department, reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly. Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	As part of its oversight responsibilities, the Audit Committee regularly discusses and reviews with management, among other items, Aptar’s compliance and cybersecurity programs.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Role of Management [Text Block]	Management reports to the Audit Committee on a quarterly basis regarding our information security programs. As part of its oversight responsibilities, the Audit Committee regularly discusses and reviews with management, among other items, Aptar’s compliance and cybersecurity programs. We also periodically test our systems for vulnerabilities and regularly engage third parties to conduct evaluations of our security controls whether through penetration testing, independent audit or consulting on best practices to address new challenges. An independent review of our cybersecurity program has been assessed against the National Institute of Standards and Technology (NIST) cybersecurity framework. In addition, we maintain cybersecurity insurance as part of our overall insurance portfolio. Our Information Security Department, reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly. Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our Information Security Department, reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. AptarGroup’s organizational structure consists of three market-focused business segments which are Aptar Pharma, Aptar Beauty and Aptar Closures. This is a strategic structure which allows us to better serve our customers and position us for long-term profitable growth. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentine peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the fourth quarter of 2023, we utilized the Blue Chip Swap and recognized a loss due to devaluation of approximately $2.5 million. Our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues at and for the year ended December 31, 2024.
ACCOUNTING ESTIMATES	ACCOUNTING ESTIMATES The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents.
ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES	ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES At December 31, 2024, we reported $658.1 million of accounts receivable, net of CECL of $15.8 million. The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Changes in CECL were not material for the year ended December 31, 2024.
INVENTORIES	INVENTORIES Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead.
ASSETS HELD FOR SALE	ASSETS HELD FOR SALE
ACQUISITIONS	ACQUISITIONS We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes significant estimates and assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment.
INVESTMENTS IN EQUITY SECURITIES	INVESTMENTS IN EQUITY SECURITIES We account for our 20% to 50% owned investments using the equity method. Under the equity method, we initially record our investment at cost and our interest in the net assets of the investee is included in the equity method investment on the Consolidated Balance Sheets. We recognize our equity in earnings in our equity method affiliates on a one-month lag basis and record our proportionate share of each investee's net income or loss into earnings after the date of investment, the adjustment of basis difference initially recognized and the other comprehensive income allocated to us from the investee. We evaluate the equity method investments for impairment under ASC 323. An impairment loss on the equity method investments is recognized in earnings when the decline in value is determined to be other-than-temporary. Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception. There were no dividends received from affiliated companies in 2024, 2023 and 2022.
PROPERTY AND DEPRECIATION	PROPERTY AND DEPRECIATION Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment.
FINITE-LIVED INTANGIBLE ASSETS	FINITE-LIVED INTANGIBLE ASSETS Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years.
IMPAIRMENT OF LONG-LIVED ASSETS	IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In those circumstances, we perform undiscounted operating cash flow analyses for asset groups at the lowest level for which cash flows are separately identifiable to determine if an impairment exists. Any impairment loss is calculated as the excess of the asset’s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal.
GOODWILL	GOODWILL The Company has evaluated the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arose in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires significant judgment and the use of estimates and assumptions related to projected revenue growth rates, projected EBITDA margins, the terminal growth factor, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate. Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management has performed this qualitative assessment as of October 1, 2024 and October 1, 2023 for each of our reporting units. Due to the realignment of the Beauty and Closures segments, management determined it appropriate to calculate the fair value of both reporting units and compare with their associated carrying amounts as of January 1, 2023. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for injectables, and the passage of time from our prior Step 1 analysis over the other pharma reporting unit, management determined it appropriate to calculate the fair value of both reporting units and compare with their associated carrying amounts as of October 1, 2024. Based on our qualitative and quantitative analysis performed over the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required.
DERIVATIVES INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction.
PURCHASE OF TREASURY STOCK	PURCHASE OF TREASURY STOCK During 2024, 2023 and 2022, we repurchased 433 thousand, 399 thousand and 860 thousand shares, respectively, all of which were returned to treasury stock. If retired, common stock is reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings.
RESEARCH & DEVELOPMENT EXPENSES	RESEARCH & DEVELOPMENT EXPENSES Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred. These costs amounted to $96.1 million, $92.8 million and $93.5 million in 2024, 2023 and 2022, respectively.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany, and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements. We have elected to include amounts paid for transferable, non-refundable U.S. energy credits as cash taxes paid in our Consolidated Statements of Cash Flows.
TRANSLATION OF FOREIGN CURRENCIES	TRANSLATION OF FOREIGN CURRENCIES The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented losses of $2.0 million, $7.3 million and $7.2 million in 2024, 2023 and 2022, respectively.
STOCK BASED COMPENSATION	STOCK-BASED COMPENSATION Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur. See Note 16 – Stock-Based Compensation for more information.
REVENUE RECOGNITION	REVENUE RECOGNITION At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results. See specific discussions about methods of accounting for control transfers of product, tooling and service contract sales in Note 2 – Revenue.
LEASES	LEASES We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in accounts payable accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise). Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability.
GOVERNMENT GRANTS	GOVERNMENT GRANTS We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost. During 2022, we received a $10.5 million government grant to be used toward the expansion of an existing injectables facility, which is reported within the investing section of the Consolidated Statements of Cash Flows to support the delivery of components for COVID-19 and other vaccines. The French government will fund approximately $14.0 million for the expansion of the facility, for which there is no clawback option. During 2022, we received $17.3 million in government grants to be used toward the construction of a new facility in Alabama, which is reported within the investing section of the Consolidated Statements of Cash Flows. This award will support expanded domestic production capacity for our active material science solutions proprietary Activ-Film technology, which is used to protect and enhance COVID-19 test kit integrity and accuracy. Under the terms of the grant agreement, the U.S. government will fund approximately $19 million to build an operating facility, for which there is no clawback provision, in exchange for the new facility to be on standby for the government for a period of 16 months after construction.
SUPPLY CHAIN FINANCE PROGRAM	SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows. As of December 31, 2024 and 2023, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities 2024 2023 SCF obligations outstanding at the beginning of the year $ 36,309 $ 30,833 Additions 160,847 163,591 Settlements (162,755) (158,115) SCF obligations outstanding at the end of the year $ 34,401 $ 36,309 Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain. To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS	ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("DISE"), which requires the disaggregation of certain expenses in the notes to the financial statements, to provide enhanced transparency into the expense captions presented on the face of the income statement. ASU 2024-03 will be effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective adoption. We are evaluating the impact of the standard on our disclosures in the Consolidated Financial Statements. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and is required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures. In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We adopted this guidance in the fourth quarter of 2024. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 18 - Segment Information for further discussion. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We adopted this guidance in the fourth quarter of 2024. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from LIBOR to SOFR for USD balances under our amended revolving credit facility. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of supply chain finance program	2024 2023 SCF obligations outstanding at the beginning of the year $ 36,309 $ 30,833 Additions 160,847 163,591 Settlements (162,755) (158,115) SCF obligations outstanding at the end of the year $ 34,401 $ 36,309

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography based on shipped to locations for the years ended December 31, 2024, 2023 and 2022 were as follows: For the Year Ended December 31, 2024 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 806,606 $ 556,642 $ 47,124 $ 232,780 $ 1,643,152 Aptar Beauty 745,198 241,115 155,692 83,725 1,225,730 Aptar Closures 218,064 347,733 83,376 64,835 714,008 Total $ 1,769,868 $ 1,145,490 $ 286,192 $ 381,340 $ 3,582,890 For the Year Ended December 31, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 779,929 $ 495,057 $ 52,074 $ 193,933 $ 1,520,993 Aptar Beauty 806,963 219,760 152,963 88,011 1,267,697 Aptar Closures 218,833 336,315 84,146 59,466 698,760 Total $ 1,805,725 $ 1,051,132 $ 289,183 $ 341,410 $ 3,487,450 For the Year Ended December 31, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 683,217 $ 446,821 $ 38,483 $ 192,735 $ 1,361,256 Aptar Beauty 715,797 280,023 134,883 91,832 1,222,535 Aptar Closures 217,162 378,503 79,482 63,311 738,458 Total $ 1,616,176 $ 1,105,347 $ 252,848 $ 347,878 $ 3,322,249
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities are as follows: Balance as of December 31, 2023 Balance as of December 31, 2024 Increase/ Contract asset (current) $ 18,033 $ 12,571 $ (5,462) Contract liability (current) 60,507 64,425 3,918 Contract liability (long-term) 37,756 40,551 2,795

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: 2024 2023 Raw materials $ 133,885 $ 145,798 Work in process 161,350 176,191 Finished goods 166,572 191,064 Total $ 461,807 $ 513,053

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill for the year ended December 31, 2024 are as follows by reporting segment: Aptar Aptar Aptar Total Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632 Reclassification due to segment change — (39,472) 39,472 — Acquisition — 4,603 114 4,717 Foreign currency exchange effects 9,705 2,955 409 13,069 Balance as of December 31, 2023 $ 508,447 $ 287,097 $ 167,874 $ 963,418 Foreign currency exchange effects (20,213) (5,811) (1,138) (27,162) Balance as of December 31, 2024 $ 488,234 $ 281,286 $ 166,736 $ 936,256
Summary of amortized intangible assets	The table below shows a summary of intangible assets for the years ended December 31, 2024 and 2023. 2024 2023 Weighted Average Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 12.6 $ 18,333 $ (2,343) $ 15,990 $ 7,362 $ (1,754) $ 5,608 Acquired technology 11.2 137,444 (80,171) 57,273 142,837 (70,520) 72,317 Customer relationships 13.6 303,502 (145,772) 157,730 308,889 (124,648) 184,241 Trademarks and trade names 8.0 42,882 (36,450) 6,432 43,932 (33,368) 10,564 License agreements and other 19.5 26,318 (8,974) 17,344 17,213 (6,732) 10,481 Total intangible assets 13.3 $ 528,479 $ (273,710) $ 254,769 $ 520,233 $ (237,022) $ 283,211
Schedule of future estimated amortization expense	Future estimated amortization expense for the years ending December 31 is as follows: 2025 $ 42,075 2026 40,923 2027 33,358 2028 29,374 2029 27,283 2030 and thereafter 81,756

ACCOUNTS PAYABLE, ACCRUED AND_2

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Components of accounts payable and accrued liabilities	At December 31, 2024 and 2023, accounts payable, accrued and other liabilities consisted of the following: 2024 2023 Accounts payable, principally trade $ 295,967 $ 328,571 Accrued employee compensation costs 211,441 222,010 Customer deposits and other unearned income 64,425 60,507 Other accrued liabilities 158,163 182,001 Total $ 729,996 $ 793,089

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of income before income taxes	Income before income taxes consists of: Years Ended December 31, 2024 2023 2022 United States $ 99,573 $ 49,681 $ 65,350 International 370,192 325,144 269,354 Total $ 469,765 $ 374,825 $ 334,704
Schedule of provision (benefit) for income taxes	The provision (benefit) for income taxes is composed of: Years Ended December 31, 2024 2023 2022 Federal: Current $ 10,933 $ 11,777 $ 12,791 Deferred (8,936) (10,931) (783) $ 1,997 $ 846 $ 12,008 State: Current $ 2,744 $ 1,300 $ 2,265 Deferred (923) (675) (99) $ 1,821 $ 625 $ 2,166 International: Current $ 103,316 $ 97,455 $ 92,199 Deferred (11,547) (8,277) (11,224) $ 91,769 $ 89,178 $ 80,975 Total $ 95,587 $ 90,649 $ 95,149
Schedule of reconciliation of actual income tax provision and the tax provision computed by applying statutory federal income tax rate	A reconciliation of the provision for income taxes with the amount computed by applying the statutory federal income tax rate of 21% to income before provision for income taxes is as follows: Years Ended December 31, 2024 2023 2022 Income tax at statutory rate $ 98,651 $ 78,713 $ 70,288 State income taxes, net of federal tax effect 1,439 362 1,475 Excess tax benefits from share-based compensation (11,041) (5,935) (3,306) Deferred tax (benefits) charges, incl. tax rate changes 2,691 (3,512) (2,349) Valuation allowance (14,625) 158 1,486 Legal entity reorganization — 3,630 5,850 Rate differential on earnings of foreign operations 21,357 18,917 19,165 Other items, net (2,885) (1,684) 2,540 Actual income tax provision $ 95,587 $ 90,649 $ 95,149 Effective income tax rate 20.3 % 24.2 % 28.4 %
Schedule of significant deferred tax assets and liabilities	Significant deferred tax assets and liabilities as of December 31, 2024 and 2023 are composed of the following temporary differences: 2024 2023 Deferred Tax Assets: Net operating loss carryforwards $ 72,766 $ 49,016 Operating and finance leases 21,712 20,440 Pension liabilities 6,472 13,608 Share-based compensation 3,747 7,326 U.S. state tax credits 5,790 6,110 Vacation and bonus 16,223 16,915 U.S. capitalized research expenditures 41,956 35,563 Inventory 6,094 7,166 Accrued liabilities and other reserves 9,598 9,622 Other 15,575 16,470 Total gross deferred tax assets $ 199,933 $ 182,236 Less valuation allowance (61,134) (48,856) Net deferred tax assets $ 138,799 $ 133,380 Deferred Tax Liabilities: Acquisition related intangibles $ 51,155 $ 57,426 Depreciation and amortization 21,325 25,541 Operating and finance leases 22,672 22,715 Other 8,059 6,988 Total gross deferred tax liabilities $ 103,211 $ 112,670 Net deferred tax assets (liabilities) $ 35,588 $ 20,710
Schedule of reconciliation of the beginning and ending amount of income tax uncertainties	A reconciliation of the beginning and ending amount of income tax uncertainties is as follows: 2024 2023 2022 Balance at January 1 $ 5,942 $ 6,919 $ 7,225 Increases based on tax positions for the current year 300 985 1,433 Increases (Decreases) based on tax positions of prior years 107 (997) (1,616) Settlements (127) (901) (80) Lapse of statute of limitations (430) (64) (43) Balance at December 31 $ 5,792 $ 5,942 $ 6,919
Schedule of major tax jurisdictions the Company files in, with the years still subject to income tax examinations	The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below: Major Tax Tax Years United States — Federal 2021-2024 United States — State 2020-2024 France 2021-2024 Germany 2022-2024 Italy 2018-2024 China 2014-2024

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of current debt	At December 31, 2024 and 2023, our revolving credit facility and overdrafts consisted of the following: 2024 2023 Revolving credit facility 3.80% $ 176,035 $ 80,662 Overdrafts — 1,132 $ 176,035 $ 81,794
Schedule of long-term obligations	At December 31, 2024 and 2023, our long-term obligations consisted of the following: December 31, 2024 December 31, 2023 Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2030 $ 15,135 $ 14,988 Senior unsecured notes 3.4%, due in 2024 — 50,000 Senior unsecured notes 3.5%, due in 2024 — 100,000 Senior unsecured notes 1.2%, due in 2024 — 220,810 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Term loan 5.8% floating, due in 2027 166,000 — Senior unsecured notes 3.6%, due in 2032, net of discount of $0.7 million 399,258 399,154 Finance Lease Liabilities 23,753 26,478 Unamortized debt issuance costs (3,830) (3,816) $ 850,316 $ 1,057,614 Current maturities of long-term obligations (162,250) (376,426) Total long-term obligations $ 688,066 $ 681,188
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 8, due annually for the next five years and thereafter are: 2025 $ 158,993 2026 155,457 2027 116,488 2028 88 2029 73 Thereafter 399,294
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at December 31, 2024 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.08 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 17.43 to 1.00 (1) Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.

LEASE COMMITMENTS (Tables)

LEASE COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the years ended December 31, 2024 and 2023 were as follows: Year Ended December 31, 2024 2023 Operating lease cost $ 20,061 $ 20,780 Finance lease cost: Amortization of right-of-use assets $ 6,803 $ 4,662 Interest on lease liabilities 1,192 1,220 Total finance lease cost $ 7,995 $ 5,882 Short-term lease and variable lease costs $ 20,149 $ 20,509
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: Year Ended December 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 20,376 $ 21,512 Operating cash flows from finance leases 1,289 1,371 Financing cash flows from finance leases 3,054 3,682 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 33,726 $ 14,514 Finance leases 1,705 2,746
Schedule of supplemental balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating Leases Operating lease right-of-use assets $ 64,213 $ 59,074 Accounts payable, accrued and other liabilities $ 17,015 $ 14,056 Operating lease liabilities 49,716 45,267 Total operating lease liabilities $ 66,731 $ 59,323 Finance Leases Property, plant and equipment, gross $ 50,319 $ 51,846 Accumulated depreciation (20,103) (15,369) Property, plant and equipment, net $ 30,216 $ 36,477 Current maturities of long-term obligations, net of unamortized debt issuance cost $ 3,563 $ 3,591 Long-term obligations, net of unamortized debt issuance cost 20,190 22,887 Total finance lease liabilities $ 23,753 $ 26,478 Weighted Average Remaining Lease Term (in years) Operating leases 4.7 3.5 Finance leases 4.9 5.3 Weighted Average Discount Rate Operating leases 5.77 % 5.52 % Finance leases 5.12 % 5.05 %
Schedule of maturities of lease liabilities	Maturities of lease liabilities as of December 31, 2024, were as follows: Operating Finance Year 1 $ 19,758 $ 4,637 Year 2 16,511 3,500 Year 3 12,267 6,683 Year 4 7,387 2,057 Year 5 5,524 7,230 Thereafter 17,649 3,227 Total lease payments 79,096 27,334 Less imputed interest (12,365) (3,581) Total $ 66,731 $ 23,753

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Change in the projected benefit obligation, plan assets at fair value and funded status	The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans. Domestic Plans Foreign Plans 2024 2023 2024 2023 Change in benefit obligation: Benefit obligation at beginning of year $ 186,013 $ 163,872 $ 104,757 $ 93,999 Service cost 9,462 9,638 6,492 5,915 Interest cost 8,968 8,631 3,488 3,642 Plan Amendment — — (17) — Curtailment/Settlement — — (1,385) (606) Prior service cost — — — (1,134) Actuarial (gain) loss (18,156) 13,989 1,370 6,906 Benefits paid (11,093) (10,117) (3,776) (6,788) Foreign currency translation adjustment (loss) gain — — (6,733) 2,823 Benefit obligation at end of year $ 175,194 $ 186,013 $ 104,196 $ 104,757 Domestic Plans Foreign Plans 2024 2023 2024 2023 Change in plan assets: Fair value of plan assets at beginning of year $ 173,735 $ 162,151 $ 72,434 $ 72,523 Actual return on plan assets 17,624 21,207 3,605 3,978 Employer contribution 495 494 3,580 477 Benefits paid (11,093) (10,117) (3,776) (6,788) Foreign currency translation adjustment — — (4,593) 2,244 Fair value of plan assets at end of year $ 180,761 $ 173,735 $ 71,250 $ 72,434 Funded status at end of year $ 5,567 $ (12,278) $ (32,946) $ (32,323)
Schedule of funded status amounts recognized in the Consolidated Balance Sheet	The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Non-current assets $ 19,739 $ 2,528 $ 3,648 $ 1,664 Current liabilities (546) (530) (46) (32) Non-current liabilities (13,626) (14,276) (36,548) (33,955) $ 5,567 $ (12,278) $ (32,946) $ (32,323)
Schedule of amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive loss	The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Net actuarial (gain) loss $ (21,495) $ 1,823 $ 16,201 $ 15,661 Net prior service cost — — (531) (162) Tax effects 6,713 1,029 (6,413) (6,463) $ (14,782) $ 2,852 $ 9,257 $ 9,036
Schedule of changes in benefit obligations and plan assets recognized in other comprehensive income	Changes in benefit obligations and plan assets recognized in other comprehensive income in 2024, 2023 and 2022 are as follows: Domestic Plans 2024 2023 2022 Current year actuarial gain (loss) $ 23,318 $ (5,161) $ 54,295 Amortization of net loss — — 6,670 $ 23,318 $ (5,161) $ 60,965 Foreign Plans 2024 2023 2022 Current year actuarial (loss) gain $ (47) $ (5,315) $ 19,181 Current year prior service cost 20 1,135 (818) Transfer actuarial gain (loss) (694) 124 17 Amortization of net loss 201 914 1,688 Amortization of prior service cost 349 177 177 $ (171) $ (2,966) $ 20,245
Components of net periodic benefit cost	Components of net periodic benefit cost: Domestic Plans 2024 2023 2022 Service cost $ 9,462 $ 9,638 $ 15,784 Interest cost 8,968 8,631 6,970 Expected return on plan assets (12,463) (12,378) (12,912) Amortization of net loss — — 6,670 Net periodic benefit cost $ 5,967 $ 5,891 $ 16,512 Foreign Plans 2024 2023 2022 Service cost $ 6,492 $ 5,915 $ 7,547 Interest cost 3,488 3,642 1,388 Expected return on plan assets (2,243) (2,340) (2,728) Amortization of net loss 201 914 1,688 Amortization of prior service cost 349 177 177 Net periodic benefit cost $ 8,287 $ 8,308 $ 8,072 Curtailment (2,205) (1) (24) Total Net periodic benefit cost $ 6,082 $ 8,307 $ 8,048
Schedule of projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets	The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Projected benefit obligation $ 14,172 $ 14,806 $ 77,645 $ 56,881 Accumulated benefit obligation 12,412 12,156 54,460 40,312 Fair value of plan assets — — 41,238 29,372
Schedule of PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets	The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2024 and 2023. Domestic Plans Foreign Plans 2024 2023 2024 2023 Projected benefit obligation $ 14,172 $ 14,806 $ 81,273 $ 81,534 Accumulated benefit obligation 12,412 12,156 57,494 56,969 Fair value of plan assets — — 44,676 47,544
Schedule of weighted-average assumptions used to determine benefit obligations and net periodic benefit cost	Assumptions: Domestic Plans Foreign Plans 2024 2023 2022 2024 2023 2022 Weighted-average assumptions used to determine benefit obligations at December 31: Discount rate 5.60 % 4.95 % 5.15 % 3.33 % 3.20 % 3.69 % Rate of compensation increase 3.24 % 3.24 % 3.20 % 3.21 % 3.20 % 3.21 % Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31: Discount rate 4.95 % 5.15 % 2.75 % 3.32 % 3.69 % 1.20 % Expected long-term return on plan assets 7.00 % 7.00 % 7.00 % 3.22 % 3.23 % 3.53 % Rate of compensation increase 3.24 % 3.20 % 3.17 % 3.21 % 3.20 % 3.20 %
Schedule of domestic and foreign pension plan weighted-average asset allocations by asset category	Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2024 and 2023 by asset category are as follows: Plan Assets: Domestic Plans Assets at December 31, Foreign Plans Assets at December 31, 2024 2023 2024 2023 Equity securities 50 % 48 % 3 % 3 % Fixed income securities 25 % 27 % 1 % 1 % Corporate debt securities — — 2 % 1 % Infrastructure 8 % 8 % — — Hedge funds 11 % 11 % — — Money market 2 % 1 % — % 1 % Investment Funds — — 94 % 94 % Real estate 4 % 5 % — — Total 100 % 100 % 100 % 100 %
Summary of fair value of pension plan assets	Domestic Fair Value Measurement at December 31, 2024 Foreign Fair Value Measurement at December 31, 2024 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 3,054 $ 3,054 $ — $ — $ 275 $ 275 $ — $ — USD — 3,054 — — — — — — EUR — — — — — 269 — — Others — — — — — 6 — — Equity Securities (a) $ 78,234 $ 78,234 $ — $ — $ 1,873 $ 1,873 $ — $ — U.S. Large Cap Equities — 45,294 — — — — — — U.S. Small Cap Equities — 10,363 — — — — — — International Equities — 22,577 — — — 1,873 — — Fixed Income (a)(b) $ 28,526 $ 28,526 $ — $ — $ 562 $ 562 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,213 $ 1,213 $ — $ — Euro Corporate Bonds (a) — — — — — 1,213 — — Investment Funds $ — $ — $ — $ — $ 67,327 $ 24,377 $ 42,950 $ — Mutual Funds in Equities (a) — — — — — 5,781 — — Mutual Funds in Bonds (a) — — — — — 14,634 — — Mutual Funds Diversified (a)(b) — — — — — 3,962 42,950 — Total Investments in Fair Value Hierarchy $ 109,814 $ 109,814 $ — $ — $ 71,250 $ 28,300 $ 42,950 $ — Investments at Net Asset Value per Share 70,947 — — — — — — — Total Investments $ 180,761 $ 109,814 $ — $ — $ 71,250 $ 28,300 $ 42,950 $ — Domestic Fair Value Measurement at December 31, 2023 Foreign Fair Value Measurement at December 31, 2023 (In Thousands $) Total (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Cash and Short-term Securities (a) $ 1,949 $ 1,949 $ — $ — $ 514 $ 514 $ — $ — USD — 1,949 — — — — — — EUR — — — — — 506 — — Others — — — — — 8 — — Equity Securities (a) $ 73,483 $ 73,483 $ — $ — $ 2,106 $ 2,106 $ — $ — U.S. Large Cap Equities — 43,156 — — — — — — U.S. Small Cap Equities — 8,864 — — — — — — International Equities — 21,463 — — — 2,106 — — Fixed Income (a)(b) $ 29,171 $ 29,171 $ — $ — $ 831 $ 831 $ — $ — Corporate debts securities $ — $ — $ — $ — $ 1,231 $ 1,231 $ — $ — Euro Corporate Bonds (a) — — — — — 1,231 — — Investment Funds $ — $ — $ — $ — $ 67,752 $ 23,513 $ 44,239 $ — Mutual Funds in Equities (a) — — — — — 5,411 — — Mutual Funds in Bonds (a) — — — — — 17,256 — — Mutual Funds Diversified (a)(b) — — — — — 846 44,239 — Total Investments in Fair Value Hierarchy $ 104,603 $ 104,603 $ — $ — $ 72,434 $ 28,195 $ 44,239 $ — Investments at Net Asset Value per Share 69,132 — — — — — — — Total Investments $ 173,735 $ 104,603 $ — $ — $ 72,434 $ 28,195 $ 44,239 $ — (a) Based on third party quotation from financial institution. (b) Based on observable market transactions.
Schedule of estimated benefit payments relating to defined benefit plans over the next ten years	As of December 31, 2024, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next 10 years: Domestic Plans Foreign Plans 2025 $ 10,191 $ 5,557 2026 10,932 3,027 2027 10,764 4,305 2028 11,915 4,874 2029 13,139 6,066 2030 - 2034 72,913 39,041

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) (Tables)	12 Months Ended
	Dec. 31, 2024
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Changes in Accumulated Other Comprehensive Income/(Loss) by component	Changes in Accumulated Other Comprehensive Income/(Loss) by Component: Foreign Defined Benefit Derivatives Total Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (79,240) 54,149 (6,666) (31,757) Amounts reclassified from accumulated other comprehensive income (loss) — 6,386 46 6,432 Net current-period other comprehensive (loss) income (79,240) 60,535 (6,620) (25,325) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive (loss) income before reclassifications 48,658 (6,711) (10,086) 31,861 Amounts reclassified from accumulated other comprehensive income — 771 — 771 Net current-period other comprehensive (loss) income 48,658 (5,940) (10,086) 32,632 Balance - December 31, 2023 $ (280,082) $ (11,891) $ (16,761) $ (308,734) Other comprehensive (loss) income before reclassifications (145,967) 17,043 7,813 (121,111) Amounts reclassified from accumulated other comprehensive income — 370 — 370 Net current-period other comprehensive (loss) income (145,967) 17,413 7,813 (120,741) Balance - December 31, 2024 $ (426,049) $ 5,522 $ (8,948) $ (429,475)
Reclassifications out of Accumulated Other Comprehensive Income/(Loss)	Reclassifications Out of Accumulated Other Comprehensive Income/(Loss): Details about Accumulated Other Amount Reclassified from Affected Line in the Statement Year Ended December 31, 2024 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 201 $ 914 $ 8,358 (1) Amortization of prior service cost 349 177 177 (1) 550 1,091 8,535 Total before tax (180) (320) (2,149) Tax benefit $ 370 $ 771 $ 6,386 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ — $ (171) Interest Expense Changes in cross currency swap: foreign exchange component — — 217 Miscellaneous, net $ — $ — $ 46 Net of tax Total reclassifications for the period $ 370 $ 771 $ 6,432 (1) These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments in the Consolidated Balance Sheets	Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023 December 31, 2024 December 31, 2023 Balance Sheet Derivatives Derivatives Derivatives Derivatives Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 572 $ — $ 386 $ — $ 572 $ — $ 386 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 622 $ — $ 221 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 11,851 — 22,199 — $ 11,851 $ 622 $ 22,199 $ 221 (1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.
Schedule of effect of derivatives designated as hedging instruments on Accumulated Other Comprehensive Income (Loss)	The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Fiscal Years Ended December 31, 2024 and December 31, 2023 Derivatives in Cash Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount 2024 2023 2024 2023 Cross currency swap contract: Foreign exchange component $ 7,813 $ (10,086) Miscellaneous, net $ — $ — $ 3,265 $ 7,813 $ (10,086) $ — $ —
Schedule of effect of derivatives not designated as hedging instruments on the Consolidated Statements of Income	The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2024 and December 31, 2023 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2024 2023 Foreign Exchange Contracts Other (Expense) Income: $ (190) $ (668) $ (190) $ (668)
Schedule of offsetting derivative assets and liabilities	Gross Amounts Net Amounts Gross Amounts not Offset Gross Financial Cash Collateral Net Description December 31, 2024 Derivative Assets $ 572 $ — $ 572 $ — $ — $ 572 Total Assets $ 572 $ — $ 572 $ — $ — $ 572 Derivative Liabilities $ 12,473 $ — $ 12,473 $ — $ — $ 12,473 Total Liabilities $ 12,473 $ — $ 12,473 $ — $ — $ 12,473 December 31, 2023 Derivative Assets $ 386 $ — $ 386 $ — $ — $ 386 Total Assets $ 386 $ — $ 386 $ — $ — $ 386 Derivative Liabilities $ 22,420 $ — $ 22,420 $ — $ — $ 22,420 Total Liabilities $ 22,420 $ — $ 22,420 $ — $ — $ 22,420

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of December 31, 2024, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 2,986 $ 2,986 $ — $ — Foreign exchange contracts (2) 572 — 572 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 9,208 $ 2,986 $ 572 $ 5,650 Liabilities Foreign exchange contracts (2) $ 622 $ — $ 622 $ — Cross currency swap contract (2) 11,851 — 11,851 — Total liabilities at fair value $ 12,473 $ — $ 12,473 $ — As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,106 $ 1,106 $ — $ — Foreign exchange contracts (2) 386 — 386 — Convertible notes (3) 5,650 — — 5,650 Total assets at fair value $ 7,142 $ 1,106 $ 386 $ 5,650 Liabilities Foreign exchange contracts (2) $ 221 $ — $ 221 $ — Cross currency swap contract (2) 22,199 — 22,199 — Total liabilities at fair value $ 22,420 $ — $ 22,420 $ — (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. (3) Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Consolidated Balance Sheets.

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	12 Months Ended
	Dec. 31, 2024
CAPITAL STOCK
Schedule of number of shares of common stock and treasury stock and the share activity	The number of shares of common stock and treasury stock and the share activity were as follows: Common Shares Treasury Shares 2024 2023 2022 2024 2023 2022 Balance at the beginning of the year 71,679,658 70,848,810 70,370,812 5,775,295 5,555,027 4,852,709 Employee option exercises 629,541 679,878 301,463 (192,123) (178,326) (157,682) Director option exercises 6,500 — — — — — Restricted stock vestings 150,849 150,970 176,535 — — — Common stock repurchases — — — 432,600 398,594 860,000 Balance at the end of the year 72,466,548 71,679,658 70,848,810 6,015,772 5,775,295 5,555,027

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Year Ended December 31, 2024 2023 (1) 2022 Fair value per stock award $ 145.79 $ 116.17 $ 141.95 Grant date stock price $ 141.00 $ 111.38 $ 114.52 Assumptions: Aptar's stock price expected volatility 18.80 % 20.00 % 20.20 % Expected average volatility of peer companies 34.80 % 39.70 % 41.70 % Correlation assumption 30.70 % 33.30 % 41.20 % Risk-free interest rate 4.51 % 3.83 % 2.04 % Dividend yield assumption 1.16 % 1.36 % 1.33 % (1) The 2023 award inputs and assumptions are related to PSU-ROIC awards with a TSR modifier.
Summary of restricted stock unit activity	A summary of RSU activity as of December 31, 2024, and changes during the period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2024 335,874 $ 115.15 514,383 $ 130.10 Granted 130,098 138.24 129,614 145.79 Vested (184,631) 119.11 (97,686) 162.24 Forfeited (4,096) 119.31 (33,085) 142.78 Nonvested at December 31, 2024 277,245 $ 123.28 513,226 $ 127.17
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Year Ended December 31, 2024 2023 2022 Compensation expense $ 40,581 $ 37,015 $ 40,937 Fair value of units vested 36,313 29,100 32,013 Intrinsic value of units vested 40,083 33,914 33,024
Schedule of share-based payment award, stock options, valuation assumptions	These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Year Ended December 31, 2024 2023 Dividend Yield 1.28 % 1.41 % Expected Stock Price Volatility 17.03 % 16.55 % Risk-free Interest Rate 4.51 % 3.57 % Expected Life of Option (years) 7.0 7.0
Summary of option activity	A summary of option activity under our stock plans as of December 31, 2024, and changes during the period then ended is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2024 2,182,784 $ 80.63 19,000 $ 66.59 Granted 249,805 141.00 — — Exercised (750,771) 71.62 (19,000) 66.59 Forfeited or expired (18,511) 87.66 — — Outstanding at December 31, 2024 1,663,307 $ 93.69 — $ — Exercisable at December 31, 2024 1,211,208 $ 80.20 — $ — Weighted-Average Remaining Contractual Term (Years): Outstanding at December 31, 2024 4.2 0.0 Exercisable at December 31, 2024 2.5 0.0 Aggregate Intrinsic Value: Outstanding at December 31, 2024 $ 105,470 $ — Exercisable at December 31, 2024 $ 93,145 $ — Intrinsic Value of Options Exercised During the Years Ended: December 31, 2024 $ 57,259 $ 1,394 December 31, 2023 $ 38,706 $ 1,978 December 31, 2022 $ 20,608 $ —
Schedule of compensation expense, and fair value related to options	Year Ended December 31, 2024 2023 2022 Compensation expense (included in SG&A) $ 6,381 $ 3,929 $ — Compensation expense (included in Cost of sales) 688 349 — Compensation expense, Total $ 7,069 $ 4,278 $ — Compensation expense, net of tax 6,880 4,278 — Grant date fair value of options vested 2,320 2,663 —

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Reconciliation of basic and diluted earnings per share	The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2024, 2023 and 2022 are as follows: Income Shares Per Share For the Year Ended December 31, 2024 Basic EPS Income available to common stockholders $ 374,541 66,334 $ 5.65 Effect of Dilutive Securities Stock options 765 Restricted stock 592 Diluted EPS Income available to common stockholders $ 374,541 67,691 $ 5.53 For the Year Ended December 31, 2023 Basic EPS Income available to common stockholders $ 284,487 65,616 $ 4.34 Effect of Dilutive Securities Stock options 874 Restricted stock 415 Diluted EPS Income available to common stockholders $ 284,487 66,905 $ 4.25 For the Year Ended December 31, 2022 Basic EPS Income available to common stockholders $ 239,288 65,402 $ 3.66 Effect of Dilutive Securities Stock options 978 Restricted stock 339 Diluted EPS Income available to common stockholders $ 239,288 66,719 $ 3.59

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Financial information regarding the company's reportable segments	Financial information regarding our reporting segments is shown below: In thousands Year Ended December 31, 2024 2023 2022 Total Sales: Aptar Pharma $ 1,644,012 $ 1,521,837 $ 1,372,449 Aptar Beauty 1,252,904 1,297,477 1,246,018 Aptar Closures 721,564 706,847 748,055 Total Sales $ 3,618,480 $ 3,526,161 $ 3,366,522 Less: Intersegment Sales: Aptar Pharma $ 860 $ 844 $ 11,193 Aptar Beauty 27,174 29,780 23,483 Aptar Closures 7,556 8,087 9,597 Total Intersegment Sales $ 35,590 $ 38,711 $ 44,273 Net Sales: Aptar Pharma $ 1,643,152 $ 1,520,993 $ 1,361,256 Aptar Beauty 1,225,730 1,267,697 1,222,535 Aptar Closures 714,008 698,760 738,458 Net Sales $ 3,582,890 $ 3,487,450 $ 3,322,249 Less: Cost of Sales (exclusive of depreciation and amortization): Aptar Pharma 834,595 797,542 709,873 Aptar Beauty 884,433 922,223 891,619 Aptar Closures 511,409 507,866 560,300 Selling, Research & Development and Administrative: Aptar Pharma 241,357 221,808 211,101 Aptar Beauty 183,903 192,831 180,910 Aptar Closures 89,913 87,930 92,697 Other Segment Items: Aptar Pharma (1,171) (990) (1,340) Aptar Beauty (2,515) (11,073) (1,881) Aptar Closures (1,456) (729) (648) Adjusted EBITDA (1): Aptar Pharma $ 568,371 $ 502,633 $ 441,622 Aptar Beauty 159,909 163,716 151,887 Aptar Closures 114,142 103,693 86,109 Adjusted EBITDA for Reportable Segments $ 842,422 $ 770,042 $ 679,618 Corporate & Other, unallocated (67,498) (62,320) (62,930) Acquisition-related costs (2) (140) (480) (231) Restructuring Initiatives (3) (13,002) (45,004) (6,597) Curtailment gain related to restructuring initiatives (4) 1,851 — — Net unrealized investment gain (loss) (5) 1,713 (2,775) (3,323) Depreciation and amortization (263,784) (248,593) (233,706) Interest Expense (43,898) (40,418) (40,827) Interest Income 12,101 4,373 2,700 Income before Income Taxes $ 469,765 $ 374,825 $ 334,704 In thousands Year Ended December 31, 2024 2023 2022 Depreciation and Amortization: Aptar Pharma $ 120,429 $ 109,366 $ 94,396 Aptar Beauty 82,931 83,399 80,498 Aptar Closures 57,326 52,095 52,866 Depreciation and Amortization for Reportable Segments 260,686 244,860 227,760 Corporate & Other 3,098 3,733 5,946 Depreciation and Amortization $ 263,784 $ 248,593 $ 233,706 Capital Expenditures: Aptar Pharma $ 148,261 $ 196,083 $ 164,396 Aptar Beauty 64,571 83,872 74,203 Aptar Closures 45,766 52,160 44,223 Capital Expenditures for Reportable Segments 258,598 332,115 282,822 Corporate & Other 23,630 14,729 29,491 Transfer of Corporate Expenditures (6) (5,747) (34,502) (1,886) Capital Expenditures $ 276,481 $ 312,342 $ 310,427 Total Assets: Aptar Pharma $ 2,057,586 $ 2,111,779 $ 1,872,843 Aptar Beauty 1,392,491 1,412,203 1,398,813 Aptar Closures 746,127 765,930 779,654 Total Assets for Reportable Segments 4,196,204 4,289,912 4,051,310 Corporate & Other 236,074 161,978 152,148 Total Assets $ 4,432,278 $ 4,451,890 $ 4,203,458 (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 19 - Acquisitions and Note 20 – Investments in Equity Securities for further details). (3) Restructuring Initiatives includes expense items for the years ended December 31, 2024, 2023 and 2022 as follows (see Note 21 – Restructuring Initiatives for further details): In thousands Year Ended December 31, 2024 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 13,019 $ 45,445 $ 6,224 Prior year initiatives (17) (441) 373 Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597 Restructuring Initiatives by Segment: Aptar Pharma $ 589 $ 4,852 $ — Aptar Beauty 8,041 20,683 5,539 Aptar Closures 3,835 17,927 1,058 Corporate & Other 537 1,542 — Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597 (4) The curtailment gain is included in the line miscellaneous income (expense), net (5) Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 20 – Investment in Equity Securities for further details). (6) The transfer of corporate expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level. The increase in 2023 relates to a project build in Suzhou, China.
Restructuring Initiatives	Restructuring Initiatives includes expense items for the years ended December 31, 2024, 2023 and 2022 as follows (see Note 21 – Restructuring Initiatives for further details): In thousands Year Ended December 31, 2024 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 13,019 $ 45,445 $ 6,224 Prior year initiatives (17) (441) 373 Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597 Restructuring Initiatives by Segment: Aptar Pharma $ 589 $ 4,852 $ — Aptar Beauty 8,041 20,683 5,539 Aptar Closures 3,835 17,927 1,058 Corporate & Other 537 1,542 — Total Restructuring Initiatives $ 13,002 $ 45,004 $ 6,597
Schedule of net sales and long-lived asset information by geographic area	The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2024, 2023 and 2022: 2024 2023 2022 Net Sales to Unaffiliated Customers (1): United States $ 1,037,968 $ 949,248 $ 972,920 Europe: France 499,795 541,333 487,650 Germany 169,891 160,812 163,277 Italy 180,101 200,817 149,725 Spain 171,779 175,101 149,987 Other Europe 748,302 727,662 665,537 Total Europe 1,769,868 1,805,725 1,616,176 China 155,502 146,026 177,855 Other Foreign Countries 619,552 586,451 555,298 Total $ 3,582,890 $ 3,487,450 $ 3,322,249 Property, Plant and Equipment, Net United States $ 349,255 $ 357,729 $ 346,382 Europe: France 527,570 550,738 482,091 Germany 229,637 225,860 194,898 Italy 44,087 42,240 42,522 Other Europe 66,546 63,864 53,317 Total Europe 867,840 882,702 772,828 China 105,613 112,017 98,469 Other Foreign Countries 124,442 125,615 125,985 Total $ 1,447,150 $ 1,478,063 $ 1,343,664 (1) Sales are attributed to countries based upon shipped to location.

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: December 31, 2024 December 31, 2023 Equity Method Investments Goldrain $ 96,667 $ — BTY 32,047 33,090 Sonmol 4,712 4,751 Desotec GmbH 948 905 Other Investments PureCycle 2,986 1,106 YAT 5,206 5,352 Loop 2,894 2,894 Others 809 1,105 $ 146,269 $ 49,203
Schedule of investment company, financial highlights	We have sold the following PCT shares related to the PureCycle investment for the years ended December 31, 2023 and 2022: Shares Sold Proceeds Realized Gain 2022 157,600 $ 1,599 $ 1,213 2023 510,449 $ 5,604 $ 4,188
Schedule of other nonoperating income (expense)	For the years ended December 31, 2024, 2023 and 2022 we recorded the following net investment gain or loss on our investment in PureCycle: 2024 2023 2022 Net investment gain (loss) $ 1,713 $ 1,413 $ (2,110)

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	As of December 31, 2024, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2023 Net Charges for the Year Ended December 31, 2024 Cash Paid Interest and Ending Reserve at December 31, 2024 Employee severance $ 27,078 $ 6,562 $ (23,791) $ (688) $ 9,161 Professional fees and other costs 2,810 6,457 (8,559) 88 796 Totals $ 29,888 $ 13,019 $ (32,350) $ (600) $ 9,957 As of December 31, 2023, we recorded the following activity associated with our optimization initiative: Beginning Reserve at December 31, 2022 Net Charges for the Year Ended December 31, 2023 Cash Paid Interest and Ending Reserve at December 31, 2023 Employee severance $ 4,993 $ 37,167 $ (12,608) $ (2,474) $ 27,078 Professional fees and other costs — 8,278 (5,486) 18 2,810 Totals $ 4,993 $ 45,445 $ (18,094) $ (2,456) $ 29,888

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) $ in Millions		3 Months Ended	12 Months Ended
	Jan. 01, 2023 segment	Dec. 31, 2023 USD ($)	Dec. 31, 2024 segment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment	3		3
Argentina
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency, gain (loss) recognized | $		$ (2.5)
Argentina | Maximum | Consolidated net revenues | Geographic concentration risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk			2%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ / shares in Units, shares in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) building	Dec. 31, 2024 USD ($) building $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Jun. 30, 2023 USD ($) building
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts receivable		$ 658,100,000
Accounts and notes receivable, less current expected credit loss		$ 15,785,000	$ 16,217,000
Assets held-for-sale					$ 700,000
Number of buildings held before sale of 2 buildings | building	3	1			3
Number of buildings sold | building	2
Gain on sale of buildings	$ 800,000
Dividends received from affiliates		$ 0	$ 0	$ 0
Common stock repurchased (retired and held in treasury) (in shares) | shares		433	399	860
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Research and development expenses incurred net of customer funded research and development or government research and development credits		$ 96,100,000	$ 92,800,000	$ 93,500,000
Foreign currency transaction gain (loss)		(2,000,000)	(7,300,000)	(7,200,000)
Supplier chain finance program, obligation		$ 34,401,000	$ 36,309,000	30,833,000
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]		Accounts payable, accrued and other liabilities
France | Government Assistance, Expansion of Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Government assistance, award amount				10,500,000
France | Scenario, Plan | Government Assistance, Expansion of Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Government assistance, award amount				14,000,000
United States | Government Assistance, New Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Government assistance, award amount				$ 17,300,000
Standby new facility period				16 months
United States | Scenario, Plan | Government Assistance, New Facility
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Government assistance, award amount				$ 19,000,000
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Supplier finance program payment terms		60 days
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Supplier finance program payment terms		120 days
Finite-Lived Intangible Assets | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Finite-lived intangible asset, useful life (in years)		1 year
Finite-Lived Intangible Assets | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Finite-lived intangible asset, useful life (in years)		50 years
Buildings and improvements | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)		10 years
Buildings and improvements | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)		40 years
Machinery and equipment | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)		3 years
Machinery and equipment | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives (in years)		15 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supply Chain Finance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
SCF [Roll Forward]
SCF obligations outstanding at the beginning of the year	$ 36,309	$ 30,833
Additions	160,847	163,591
Settlements	(162,755)	(158,115)
SCF obligations outstanding at the end of the year	$ 34,401	$ 36,309

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
REVENUE
Net Sales	$ 3,582,890	$ 3,487,450	$ 3,322,249
Aptar Pharma
REVENUE
Net Sales	1,643,152	1,520,993	1,361,256
Aptar Beauty
REVENUE
Net Sales	1,225,730	1,267,697	1,222,535
Aptar Closures
REVENUE
Net Sales	714,008	698,760	738,458
Europe
REVENUE
Net Sales	1,769,868	1,805,725	1,616,176
Europe | Aptar Pharma
REVENUE
Net Sales	806,606	779,929	683,217
Europe | Aptar Beauty
REVENUE
Net Sales	745,198	806,963	715,797
Europe | Aptar Closures
REVENUE
Net Sales	218,064	218,833	217,162
Domestic
REVENUE
Net Sales	1,145,490	1,051,132	1,105,347
Domestic | Aptar Pharma
REVENUE
Net Sales	556,642	495,057	446,821
Domestic | Aptar Beauty
REVENUE
Net Sales	241,115	219,760	280,023
Domestic | Aptar Closures
REVENUE
Net Sales	347,733	336,315	378,503
Latin America
REVENUE
Net Sales	286,192	289,183	252,848
Latin America | Aptar Pharma
REVENUE
Net Sales	47,124	52,074	38,483
Latin America | Aptar Beauty
REVENUE
Net Sales	155,692	152,963	134,883
Latin America | Aptar Closures
REVENUE
Net Sales	83,376	84,146	79,482
Asia
REVENUE
Net Sales	381,340	341,410	347,878
Asia | Aptar Pharma
REVENUE
Net Sales	232,780	193,933	192,735
Asia | Aptar Beauty
REVENUE
Net Sales	83,725	88,011	91,832
Asia | Aptar Closures
REVENUE
Net Sales	$ 64,835	$ 59,466	$ 63,311

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 12,571	$ 18,033
Increase / (decrease) in contract asset (current)	(5,462)
Contract liability (current)	64,425	60,507
Increase / (decrease) in contract liability (current)	3,918
Contract liability (long-term)	40,551	$ 37,756
Increase / (decrease) in contract liability (long-term)	2,795
Revenue recognized previously included in current contract liabilities	122,900
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 54,300

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventories, by component
Raw materials	$ 133,885	$ 145,798
Work in process	161,350	176,191
Finished goods	166,572	191,064
Total	$ 461,807	$ 513,053

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Changes in the carrying amount of goodwill
Goodwill beginning balance	$ 963,418	$ 945,632
Reclassification due to segment change		0
Acquisition		4,717
Foreign currency exchange effects	(27,162)	13,069
Goodwill ending balance	936,256	963,418
Operating Segments | Aptar Pharma
Changes in the carrying amount of goodwill
Goodwill beginning balance	508,447	498,742
Reclassification due to segment change		0
Acquisition		0
Foreign currency exchange effects	(20,213)	9,705
Goodwill ending balance	488,234	508,447
Operating Segments | Aptar Beauty
Changes in the carrying amount of goodwill
Goodwill beginning balance	287,097	319,011
Reclassification due to segment change		(39,472)
Acquisition		4,603
Foreign currency exchange effects	(5,811)	2,955
Goodwill ending balance	281,286	287,097
Operating Segments | Aptar Closures
Changes in the carrying amount of goodwill
Goodwill beginning balance	167,874	127,879
Reclassification due to segment change		39,472
Acquisition		114
Foreign currency exchange effects	(1,138)	409
Goodwill ending balance	$ 166,736	$ 167,874

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)		12 Months Ended
	Jan. 01, 2023 USD ($) segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of realigned segments | segment	2
Goodwill, amount transferred between reporting unit	$ 39,500,000
Impairment of goodwill		$ 0	$ 0	$ 0
Amortized intangible assets:
Payments to acquire intangible assets		17,709,000	$ 6,061,000	$ 5,189,000
Patents
Amortized intangible assets:
Payments to acquire intangible assets		$ 12,400,000

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amortized intangible assets:
Gross Carrying Amount	$ 528,479	$ 520,233
Accumulated Amortization	(273,710)	(237,022)
Net Value	254,769	283,211
Aggregate amortization expense	$ 44,117	44,720	$ 43,574
Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	13 years 3 months 18 days
Patents
Amortized intangible assets:
Gross Carrying Amount	$ 18,333	7,362
Accumulated Amortization	(2,343)	(1,754)
Net Value	$ 15,990	5,608
Patents | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	12 years 7 months 6 days
Acquired technology
Amortized intangible assets:
Gross Carrying Amount	$ 137,444	142,837
Accumulated Amortization	(80,171)	(70,520)
Net Value	$ 57,273	72,317
Acquired technology | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	11 years 2 months 12 days
Customer relationships
Amortized intangible assets:
Gross Carrying Amount	$ 303,502	308,889
Accumulated Amortization	(145,772)	(124,648)
Net Value	$ 157,730	184,241
Customer relationships | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	13 years 7 months 6 days
Trademarks and trade names
Amortized intangible assets:
Gross Carrying Amount	$ 42,882	43,932
Accumulated Amortization	(36,450)	(33,368)
Net Value	$ 6,432	10,564
Trademarks and trade names | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	8 years
License agreements and other
Amortized intangible assets:
Gross Carrying Amount	$ 26,318	17,213
Accumulated Amortization	(8,974)	(6,732)
Net Value	$ 17,344	$ 10,481
License agreements and other | Weighted Average
Amortized intangible assets:
Weighted Average Amortization Period (Years)	19 years 6 months

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 42,075
2026	40,923
2027	33,358
2028	29,374
2029	27,283
2030 and thereafter	$ 81,756

ACCOUNTS PAYABLE, ACCRUED AND_3

ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable, principally trade	$ 295,967	$ 328,571
Accrued employee compensation costs	211,441	222,010
Customer deposits and other unearned income	64,425	60,507
Other accrued liabilities	158,163	182,001
Total	$ 729,996	$ 793,089

INCOME TAXES - Provision (Benef

INCOME TAXES - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income before income taxes:
United States	$ 99,573	$ 49,681	$ 65,350
International	370,192	325,144	269,354
Income before Income Taxes	469,765	374,825	334,704
Federal:
Current	10,933	11,777	12,791
Deferred	(8,936)	(10,931)	(783)
Federal provision (benefit) for income tax	1,997	846	12,008
State:
Current	2,744	1,300	2,265
Deferred	(923)	(675)	(99)
State provision (benefit) for income tax	1,821	625	2,166
International:
Current	103,316	97,455	92,199
Deferred	(11,547)	(8,277)	(11,224)
International, provision (benefit) for income tax	91,769	89,178	80,975
Actual income tax provision	$ 95,587	$ 90,649	$ 95,149

INCOME TAXES - Effective Income

INCOME TAXES - Effective Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income tax at statutory rate	$ 98,651	$ 78,713	$ 70,288
State income taxes, net of federal tax effect	1,439	362	1,475
Excess tax benefits from share-based compensation	(11,041)	(5,935)	(3,306)
Deferred tax (benefits) charges, incl. tax rate changes	2,691	(3,512)	(2,349)
Valuation allowance	(14,625)	158	1,486
Legal entity reorganization	0	3,630	5,850
Rate differential on earnings of foreign operations	21,357	18,917	19,165
Other items, net	(2,885)	(1,684)	2,540
Actual income tax provision	$ 95,587	$ 90,649	$ 95,149
Effective income tax rate	20.30%	24.20%	28.40%

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Valuation Allowance [Line Items]
Excess tax benefits from share-based compensation	$ 11,041	$ 5,935	$ 3,306
Legal entity reorganization	0	3,630	5,850
Deferred tax assets, valuation allowance	61,134	48,856
Net operating loss carryforwards	72,766	49,016
Decrease in unrecognized tax benefits is reasonably possible	1,300
Tax-effected net operating loss subject to expiration	9,100
Tax-effected net operating loss carryforwards not subject to expiration	63,700
Unrecognized Tax Benefits	5,792	5,942	6,919	$ 7,225
Unrecognized tax benefits, income tax penalties and interest accrued	3,600	3,400	4,900
Unrecognized tax benefits, income tax penalties and interest expense	200	$ 200	$ 300
Luxembourg
Valuation Allowance [Line Items]
Tax benefit from revised assessment of tax losses	11,000
Deferred tax asset for tax losses in Luxembourg	29,500
Valuation allowance related to deferred tax asset for tax losses in Luxembourg	18,500
State and Local Jurisdiction
Valuation Allowance [Line Items]
Tax-effected net operating loss subject to expiration	5,800
Minimum | Luxembourg
Valuation Allowance [Line Items]
Decrease in unrecognized tax benefits is reasonably possible	7,000
Minimum | Foreign Tax Jurisdiction
Valuation Allowance [Line Items]
Estimated additional tax payable on previously unremitted earnings	15,000
Maximum | Luxembourg
Valuation Allowance [Line Items]
Decrease in unrecognized tax benefits is reasonably possible	10,000
Maximum | Foreign Tax Jurisdiction
Valuation Allowance [Line Items]
Estimated additional tax payable on previously unremitted earnings	20,000
Deferred tax assets for specified locations
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	56,900
Deferred tax assets related to tax credit carryforwards, U.S. state
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	$ 4,000

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred Tax Assets:
Net operating loss carryforwards	$ 72,766	$ 49,016
Operating and finance leases	21,712	20,440
Pension liabilities	6,472	13,608
Share-based compensation	3,747	7,326
U.S. state tax credits	5,790	6,110
Vacation and bonus	16,223	16,915
U.S. capitalized research expenditures	41,956	35,563
Inventory	6,094	7,166
Accrued liabilities and other reserves	9,598	9,622
Other	15,575	16,470
Total gross deferred tax assets	199,933	182,236
Less valuation allowance	(61,134)	(48,856)
Net deferred tax assets	138,799	133,380
Deferred Tax Liabilities:
Acquisition related intangibles	51,155	57,426
Depreciation and amortization	21,325	25,541
Operating and finance leases	22,672	22,715
Other	8,059	6,988
Total gross deferred tax liabilities	103,211	112,670
Net deferred tax assets	$ 35,588	$ 20,710

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of Income Tax Uncertainties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of the beginning and ending amount of income tax uncertainties
Balance at the beginning of period	$ 5,942	$ 6,919	$ 7,225
Increases based on tax positions for the current year	300	985	1,433
Increases (Decreases) based on tax positions of prior years	107	(997)	(1,616)
Settlements	(127)	(901)	(80)
Lapse of statute of limitations	(430)	(64)	(43)
Balance at the end of period	$ 5,792	$ 5,942	$ 6,919

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	$ 176,035	$ 81,794
Revolving credit facility
Short-term Debt [Line Items]
Interest rate	3.80%
Revolving credit facility and overdrafts	$ 176,035	80,662
Overdrafts
Short-term Debt [Line Items]
Revolving credit facility and overdrafts	$ 0	$ 1,132

DEBT - Narrative (Details)

DEBT - Narrative (Details) € in Millions						12 Months Ended
	Sep. 05, 2024 USD ($)	Jul. 19, 2024 EUR (€)	Jul. 02, 2024 USD ($) extension	Feb. 26, 2024 USD ($)	Jul. 19, 2023 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	Oct. 31, 2020 USD ($)
Debt Instrument [Line Items]
Short-term borrowing						$ 176,035,000	$ 81,794,000
Money Market Borrowing Arrangement
Debt Instrument [Line Items]
Short-term borrowing, maximum borrowing capacity										$ 30,000,000
Short-term borrowing						0	0
Amended Revolving Credit Facility Maturing In July 2029
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 600,000,000
Line of credit facility, increase limit			$ 300,000,000
Line of credit facility, number of extensions | extension			2
Line of credit facility, duration of extension (in years)			1 year
Long-term line of credit							36,500,000
Compensating balance, amount						0
Amended Revolving Credit Facility Maturing In July 2029 | Subsidiaries
Debt Instrument [Line Items]
Long-term line of credit						0	0
Amended Revolving Credit Facility Maturing In July 2029 | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit						176,000,000	44,200,000	€ 170	€ 40
Unsecured Lines Of Credit
Debt Instrument [Line Items]
Interest and fees						9,500,000	3,900,000
Line of credit facility, average outstanding amount						$ 170,600,000	$ 60,500,000
Short-term debt, weighted average interest rate, over time						5.10%	5.20%
Senior Unsecured Notes 3.49 Percent Due In 2024
Debt Instrument [Line Items]
Debt instrument, repaid				$ 100,000,000
Interest rate on notes (as a percent)				3.49%
Senior Unsecured Notes 1.17 Percent Due In 2024
Debt Instrument [Line Items]
Debt instrument, repaid | €		€ 200
Interest rate on notes (as a percent)		1.17%
Senior Unsecured Notes 3.4 Percent Due In September 2024
Debt Instrument [Line Items]
Debt instrument, repaid	$ 50,000,000
Interest rate on notes (as a percent)	3.40%
Senior Unsecured Notes 0.98 Percent Due In 2023
Debt Instrument [Line Items]
Debt instrument, repaid | €					€ 100
Interest rate on notes (as a percent)					0.98%

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Jul. 06, 2022
Debt Instrument [Line Items]
Finance Lease Liabilities	$ 23,753	$ 26,478
Unamortized debt issuance costs	(3,830)	(3,816)
Long-term debt and lease obligation, including current maturities	850,316	1,057,614
Current maturities of long-term obligations	(162,250)	(376,426)
Total long-term obligations	$ 688,066	681,188
Consolidated leverage ratio	1.08
Consolidated interest coverage ratio	17.43
Minimum
Debt Instrument [Line Items]
Consolidated interest coverage ratio	3
Maximum
Debt Instrument [Line Items]
Consolidated leverage ratio	3.50
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2030
Debt Instrument [Line Items]
Long-term debt, gross	$ 15,135	14,988
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2030 | Minimum
Debt Instrument [Line Items]
Interest rate on notes (as a percent)	0%
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2030 | Maximum
Debt Instrument [Line Items]
Interest rate on notes (as a percent)	2.25%
Senior unsecured notes 3.4%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	50,000
Interest rate on notes (as a percent)	3.40%
Senior unsecured notes 3.5%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	100,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.2%, due in 2024
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	220,810
Interest rate on notes (as a percent)	1.20%
Senior unsecured notes 3.6%, due in 2025
Debt Instrument [Line Items]
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2026
Debt Instrument [Line Items]
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.60%
Term loan 5.8% floating, due in 2027
Debt Instrument [Line Items]
Long-term debt, gross	$ 166,000	0
Interest rate on notes (as a percent)	5.80%
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.7 million
Debt Instrument [Line Items]
Long-term debt, gross	$ 399,258	$ 399,154
Interest rate on notes (as a percent)	3.60%		3.60%
Debt instrument, discount	$ 700

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 158,993
2026	155,457
2027	116,488
2028	88
2029	73
Thereafter	$ 399,294

LEASE COMMITMENTS - Components

LEASE COMMITMENTS - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Components of lease expense:
Operating lease cost	$ 20,061	$ 20,780
Finance lease cost:
Amortization of right-of-use assets	6,803	4,662
Interest on lease liabilities	1,192	1,220
Total finance lease cost	7,995	5,882
Short-term lease and variable lease costs	$ 20,149	$ 20,509

LEASE COMMITMENTS - Supplementa

LEASE COMMITMENTS - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 20,376	$ 21,512
Operating cash flows from finance leases	1,289	1,371
Financing cash flows from finance leases	3,054	3,682
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	33,726	14,514
Finance leases	$ 1,705	$ 2,746

LEASE COMMITMENTS - Supplemen_2

LEASE COMMITMENTS - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Operating Leases
Operating lease right-of-use assets	$ 64,213	$ 59,074
Accounts payable, accrued and other liabilities	17,015	14,056
Operating lease liabilities	49,716	45,267
Total operating lease liabilities	$ 66,731	$ 59,323
Operating lease, liability, current, Statement of Financial Position [Extensible List]	Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities
Finance Leases
Property, plant and equipment, gross	$ 50,319	$ 51,846
Accumulated depreciation	(20,103)	(15,369)
Property, plant and equipment, net	30,216	36,477
Current maturities of long-term obligations, net of unamortized debt issuance cost	3,563	3,591
Long-term obligations, net of unamortized debt issuance cost	20,190	22,887
Total finance lease liabilities	$ 23,753	$ 26,478
Finance lease, right-of-use asset, Statement of Financial Position [Extensible List]	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Finance lease, liability, current, Statement of Financial Position [Extensible List]	Long-Term Debt and Lease Obligation, Current	Long-Term Debt and Lease Obligation, Current
Finance lease, liability, noncurrent, Statement of Financial Position [Extensible List]	Long-Term Obligations, net of unamortized debt issuance costs	Long-Term Obligations, net of unamortized debt issuance costs
Weighted Average Remaining Lease Term (in years)
Operating leases	4 years 8 months 12 days	3 years 6 months
Finance leases	4 years 10 months 24 days	5 years 3 months 18 days
Weighted Average Discount Rate
Operating leases	5.77%	5.52%
Finance leases	5.12%	5.05%

LEASE COMMITMENTS - Maturities

LEASE COMMITMENTS - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Operating Leases
Year 1	$ 19,758
Year 2	16,511
Year 3	12,267
Year 4	7,387
Year 5	5,524
Thereafter	17,649
Total lease payments	79,096
Less imputed interest	(12,365)
Total operating lease liabilities	66,731	$ 59,323
Finance Leases
Year 1	4,637
Year 2	3,500
Year 3	6,683
Year 4	2,057
Year 5	7,230
Thereafter	3,227
Total lease payments	27,334
Less imputed interest	(3,581)
Total finance lease liabilities	$ 23,753	$ 26,478

LEASE COMMITMENTS - Narrative (

LEASE COMMITMENTS - Narrative (Details)	Dec. 31, 2024 USD ($)
Operating Leased Assets [Line Items]
Unconditional purchase commitment	$ 46,100,000
Minimum
Operating Leased Assets [Line Items]
Lessee, operating lease, lease not yet commenced, term of contract	2 years
Maximum
Operating Leased Assets [Line Items]
Lessee, operating lease, lease not yet commenced, term of contract	4 years
Operating Lease, Lease Not yet Commenced
Operating Leased Assets [Line Items]
Unconditional purchase commitment	$ 900,000
Financing Lease, Lease Not yet Commenced
Operating Leased Assets [Line Items]
Unconditional purchase commitment	$ 0

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Components of net periodic benefit cost:
Curtailment	$ (1,851)	$ 0	$ 0
United States
Change in benefit obligation:
Benefit obligation at beginning of year	186,013	163,872
Service cost	9,462	9,638	15,784
Interest cost	8,968	8,631	6,970
Plan Amendment	0	0
Curtailment/Settlement	0	0
Prior service cost	0	0
Actuarial (gain) loss	(18,156)	13,989
Benefits paid	(11,093)	(10,117)
Foreign currency translation adjustment (loss) gain	0	0
Benefit obligation at end of year	175,194	186,013	163,872
Change in plan assets:
Fair value of plan assets at beginning of year	173,735	162,151
Actual return on plan assets	17,624	21,207
Employer contribution	495	494
Benefits paid	(11,093)	(10,117)
Foreign currency translation adjustment	0	0
Fair value of plan assets at end of year	180,761	173,735	162,151
Funded status at end of year	5,567	(12,278)
Funded status amounts recognized in Consolidated Balance Sheet
Non-current assets	19,739	2,528
Current liabilities	(546)	(530)
Non-current liabilities	(13,626)	(14,276)
Funded status amount	5,567	(12,278)
Amounts recognized in accumulated other comprehensive loss
Net actuarial (gain) loss	(21,495)	1,823
Net prior service cost	0	0
Tax effects	6,713	1,029
Net amount recognized	(14,782)	2,852
Changes in benefit obligations and plan assets recognized in other comprehensive income
Current year actuarial (loss) gain	23,318	(5,161)	54,295
Amortization of net loss	0	0	6,670
Net amount recognized	23,318	(5,161)	60,965
Components of net periodic benefit cost:
Service cost	9,462	9,638	15,784
Interest cost	8,968	8,631	6,970
Expected return on plan assets	(12,463)	(12,378)	(12,912)
Amortization of net loss	0	0	6,670
Net periodic benefit cost	5,967	5,891	$ 16,512
Accumulated benefit obligation	163,400	171,600
Projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets
Projected benefit obligation	14,172	14,806
Accumulated benefit obligation	12,412	12,156
Fair value of plan assets	0	0
PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets
Projected benefit obligation	14,172	14,806
Accumulated benefit obligation	12,412	12,156
Fair value of plan assets	$ 0	$ 0
Weighted-average assumptions used to determine benefit obligations
Discount rate	5.60%	4.95%	5.15%
Rate of compensation increase	3.24%	3.24%	3.20%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate	4.95%	5.15%	2.75%
Expected long-term return on plan assets	7%	7%	7%
Rate of compensation increase	3.24%	3.20%	3.17%
Plan assets, actual allocation percentage	100%	100%
Plan Assets:
Total investments	$ 180,761	$ 173,735	$ 162,151
United States | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	173,735
Fair value of plan assets at end of year	180,761	173,735
Plan Assets:
Total investments	$ 180,761	$ 173,735
United States | Equity securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	50%	48%
Target allocation percentage	63%
United States | Fixed income securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	25%	27%
United States | Corporate debt securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
United States | Investment Funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
United States | Infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	8%	8%
United States | Hedge funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	11%	11%
United States | Money market
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	2%	1%
United States | Real estate
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	4%	5%
United States | Fixed income securities and infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Target allocation percentage	37%
United States | Fair Value, Inputs, Level 1, 2 and 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	$ 104,603
Fair value of plan assets at end of year	109,814	$ 104,603
Plan Assets:
Total investments	109,814	104,603
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,949
Fair value of plan assets at end of year	3,054	1,949
Plan Assets:
Total investments	3,054	1,949
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	73,483
Fair value of plan assets at end of year	78,234	73,483
Plan Assets:
Total investments	78,234	73,483
United States | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	29,171
Fair value of plan assets at end of year	28,526	29,171
Plan Assets:
Total investments	28,526	29,171
United States | Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	104,603
Fair value of plan assets at end of year	109,814	104,603
Plan Assets:
Total investments	109,814	104,603
United States | Level 1 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,949
Fair value of plan assets at end of year	3,054	1,949
Plan Assets:
Total investments	3,054	1,949
United States | Level 1 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,949
Fair value of plan assets at end of year	3,054	1,949
Plan Assets:
Total investments	3,054	1,949
United States | Level 1 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	73,483
Fair value of plan assets at end of year	78,234	73,483
Plan Assets:
Total investments	78,234	73,483
United States | Level 1 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	43,156
Fair value of plan assets at end of year	45,294	43,156
Plan Assets:
Total investments	45,294	43,156
United States | Level 1 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	8,864
Fair value of plan assets at end of year	10,363	8,864
Plan Assets:
Total investments	10,363	8,864
United States | Level 1 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	21,463
Fair value of plan assets at end of year	22,577	21,463
Plan Assets:
Total investments	22,577	21,463
United States | Level 1 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	29,171
Fair value of plan assets at end of year	28,526	29,171
Plan Assets:
Total investments	28,526	29,171
United States | Level 1 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 1 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 2 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Level 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
United States | Net Asset Value per Share | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	69,132
Fair value of plan assets at end of year	70,947	69,132
Plan Assets:
Total investments	70,947	69,132
Foreign Plans
Change in benefit obligation:
Benefit obligation at beginning of year	104,757	93,999
Service cost	6,492	5,915	7,547
Interest cost	3,488	3,642	1,388
Plan Amendment	(17)	0
Curtailment/Settlement	(1,385)	(606)
Prior service cost	0	(1,134)
Actuarial (gain) loss	1,370	6,906
Benefits paid	(3,776)	(6,788)
Foreign currency translation adjustment (loss) gain	(6,733)	2,823
Benefit obligation at end of year	104,196	104,757	93,999
Change in plan assets:
Fair value of plan assets at beginning of year	72,434	72,523
Actual return on plan assets	3,605	3,978
Employer contribution	3,580	477
Benefits paid	(3,776)	(6,788)
Foreign currency translation adjustment	(4,593)	2,244
Fair value of plan assets at end of year	71,250	72,434	72,523
Funded status at end of year	(32,946)	(32,323)
Funded status amounts recognized in Consolidated Balance Sheet
Non-current assets	3,648	1,664
Current liabilities	(46)	(32)
Non-current liabilities	(36,548)	(33,955)
Funded status amount	(32,946)	(32,323)
Amounts recognized in accumulated other comprehensive loss
Net actuarial (gain) loss	16,201	15,661
Net prior service cost	(531)	(162)
Tax effects	(6,413)	(6,463)
Net amount recognized	9,257	9,036
Changes in benefit obligations and plan assets recognized in other comprehensive income
Current year actuarial (loss) gain	(47)	(5,315)	19,181
Current year prior service cost	20	1,135	(818)
Transfer actuarial gain (loss)	(694)	124	17
Amortization of net loss	201	914	1,688
Amortization of prior service cost	349	177	177
Net amount recognized	(171)	(2,966)	20,245
Components of net periodic benefit cost:
Service cost	6,492	5,915	7,547
Interest cost	3,488	3,642	1,388
Expected return on plan assets	(2,243)	(2,340)	(2,728)
Amortization of net loss	201	914	1,688
Amortization of prior service cost	349	177	177
Net periodic benefit cost	8,287	8,308	8,072
Curtailment	(2,205)	(1)	(24)
Total Net periodic benefit cost	6,082	8,307	$ 8,048
Accumulated benefit obligation	80,200	80,100
Projected benefit obligation ("PBO"), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets
Projected benefit obligation	77,645	56,881
Accumulated benefit obligation	54,460	40,312
Fair value of plan assets	41,238	29,372
PBO, ABO, and fair value of plan assets for all pension plans with a PBO in excess of plan assets
Projected benefit obligation	81,273	81,534
Accumulated benefit obligation	57,494	56,969
Fair value of plan assets	$ 44,676	$ 47,544
Weighted-average assumptions used to determine benefit obligations
Discount rate	3.33%	3.20%	3.69%
Rate of compensation increase	3.21%	3.20%	3.21%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate	3.32%	3.69%	1.20%
Expected long-term return on plan assets	3.22%	3.23%	3.53%
Rate of compensation increase	3.21%	3.20%	3.20%
Plan assets, actual allocation percentage	100%	100%
Plan Assets:
Total investments	$ 71,250	$ 72,434	$ 72,523
Foreign Plans | Equity securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	3%	3%
Foreign Plans | Fixed income securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	1%	1%
Foreign Plans | Corporate debt securities
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	2%	1%
Foreign Plans | Investment Funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	94%	94%
Target allocation percentage	100%
Foreign Plans | Infrastructure
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Hedge funds
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Money market
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	1%
Foreign Plans | Real estate
Weighted-average assumptions used to determine net periodic benefit cost
Plan assets, actual allocation percentage	0%	0%
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	$ 72,434
Fair value of plan assets at end of year	71,250	$ 72,434
Plan Assets:
Total investments	71,250	72,434
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	514
Fair value of plan assets at end of year	275	514
Plan Assets:
Total investments	275	514
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	2,106
Fair value of plan assets at end of year	1,873	2,106
Plan Assets:
Total investments	1,873	2,106
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	831
Fair value of plan assets at end of year	562	831
Plan Assets:
Total investments	562	831
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,231
Fair value of plan assets at end of year	1,213	1,231
Plan Assets:
Total investments	1,213	1,231
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	67,752
Fair value of plan assets at end of year	67,327	67,752
Plan Assets:
Total investments	67,327	67,752
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	28,195
Fair value of plan assets at end of year	28,300	28,195
Plan Assets:
Total investments	28,300	28,195
Foreign Plans | Level 1 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	514
Fair value of plan assets at end of year	275	514
Plan Assets:
Total investments	275	514
Foreign Plans | Level 1 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	506
Fair value of plan assets at end of year	269	506
Plan Assets:
Total investments	269	506
Foreign Plans | Level 1 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	8
Fair value of plan assets at end of year	6	8
Plan Assets:
Total investments	6	8
Foreign Plans | Level 1 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	2,106
Fair value of plan assets at end of year	1,873	2,106
Plan Assets:
Total investments	1,873	2,106
Foreign Plans | Level 1 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 1 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	2,106
Fair value of plan assets at end of year	1,873	2,106
Plan Assets:
Total investments	1,873	2,106
Foreign Plans | Level 1 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	831
Fair value of plan assets at end of year	562	831
Plan Assets:
Total investments	562	831
Foreign Plans | Level 1 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,231
Fair value of plan assets at end of year	1,213	1,231
Plan Assets:
Total investments	1,213	1,231
Foreign Plans | Level 1 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	1,231
Fair value of plan assets at end of year	1,213	1,231
Plan Assets:
Total investments	1,213	1,231
Foreign Plans | Level 1 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	23,513
Fair value of plan assets at end of year	24,377	23,513
Plan Assets:
Total investments	24,377	23,513
Foreign Plans | Level 1 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	5,411
Fair value of plan assets at end of year	5,781	5,411
Plan Assets:
Total investments	5,781	5,411
Foreign Plans | Level 1 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	17,256
Fair value of plan assets at end of year	14,634	17,256
Plan Assets:
Total investments	14,634	17,256
Foreign Plans | Level 1 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	846
Fair value of plan assets at end of year	3,962	846
Plan Assets:
Total investments	3,962	846
Foreign Plans | Level 2 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	44,239
Fair value of plan assets at end of year	42,950	44,239
Plan Assets:
Total investments	42,950	44,239
Foreign Plans | Level 2 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	44,239
Fair value of plan assets at end of year	42,950	44,239
Plan Assets:
Total investments	42,950	44,239
Foreign Plans | Level 2 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 2 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	44,239
Fair value of plan assets at end of year	42,950	44,239
Plan Assets:
Total investments	42,950	44,239
Foreign Plans | Level 3 | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | USD | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | EUR | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Cash and Short Term Securities | Others | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Equity securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | U.S. Large Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | U.S. Small Cap Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | International Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Fixed income securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Corporate debt securities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Euro Corporate Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Investment Funds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds in Equities | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds in Bonds | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	0	0
Foreign Plans | Level 3 | Mutual Funds Diversified | Fair Value, Recurring
Change in plan assets:
Fair value of plan assets at beginning of year	0
Fair value of plan assets at end of year	0	0
Plan Assets:
Total investments	$ 0	$ 0

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Contributions Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Changes in the benefit obligations and plan assets
Contribution plan to SERP plans	$ 500,000
Expected contribution to SERP plans in next fiscal year	500,000
United States
Changes in the benefit obligations and plan assets
Minimum funding requirement by employer	0
Expected contribution to defined benefit plan in next fiscal year	10,000,000
Employer contribution	495,000	$ 494,000
Foreign Plans
Changes in the benefit obligations and plan assets
Expected contribution to defined benefit plan in next fiscal year	800,000
Employer contribution	$ 3,580,000	$ 477,000

RETIREMENT AND DEFERRED COMPE_5

RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Estimated Benefit Payments to Defined Benefit Plans (Details) $ in Thousands	Dec. 31, 2024 USD ($)
United States
Changes in the benefit obligations and plan assets
2025	$ 10,191
2026	10,932
2027	10,764
2028	11,915
2029	13,139
2030 - 2034	72,913
Foreign Plans
Changes in the benefit obligations and plan assets
2025	5,557
2026	3,027
2027	4,305
2028	4,874
2029	6,066
2030 - 2034	$ 39,041

RETIREMENT AND DEFERRED COMPE_6

RETIREMENT AND DEFERRED COMPENSATION PLANS - Other Plans Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
United States
Defined contribution plan
Total contributions by company	$ 5	$ 5	$ 5
United States | Aptar Retirement Savings Account
Defined contribution plan
Total contributions by company	$ 3.3	2.7	2
United States | Maximum
Defined contribution plan
Employer matching contribution as a percentage of salary	3%
United States | Maximum | Aptar Retirement Savings Account
Defined contribution plan
Employer matching contribution as a percentage of salary	5%
United States | Other Plans
Defined contribution plan
Liability, defined benefit plan	$ 14.2	14.8
Foreign Plans
Defined contribution plan
Total contributions by company	$ 3	$ 3.1	$ 2.9

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) - Changes in Accumulated Other Comprehensive Income/(Loss) by Component (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated other comprehensive income activity
Balance at beginning of period	$ 2,321,298	$ 2,068,204	$ 1,984,600
Total other comprehensive (loss) income	(120,581)	32,920	(26,516)
Balance at end of period	2,485,924	2,321,298	2,068,204
Accumulated Other Comprehensive (Loss)Income
Accumulated other comprehensive income activity
Balance at beginning of period	(308,734)	(341,366)	(316,041)
Other comprehensive (loss) income before reclassifications	(121,111)	31,861	(31,757)
Amounts reclassified from accumulated other comprehensive income (loss)	370	771	6,432
Total other comprehensive (loss) income	(120,741)	32,632	(25,325)
Balance at end of period	(429,475)	(308,734)	(341,366)
Foreign Currency
Accumulated other comprehensive income activity
Balance at beginning of period	(280,082)	(328,740)	(249,500)
Other comprehensive (loss) income before reclassifications	(145,967)	48,658	(79,240)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	0
Total other comprehensive (loss) income	(145,967)	48,658	(79,240)
Balance at end of period	(426,049)	(280,082)	(328,740)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at beginning of period	(11,891)	(5,951)	(66,486)
Other comprehensive (loss) income before reclassifications	17,043	(6,711)	54,149
Amounts reclassified from accumulated other comprehensive income (loss)	370	771	6,386
Total other comprehensive (loss) income	17,413	(5,940)	60,535
Balance at end of period	5,522	(11,891)	(5,951)
Derivatives
Accumulated other comprehensive income activity
Balance at beginning of period	(16,761)	(6,675)	(55)
Other comprehensive (loss) income before reclassifications	7,813	(10,086)	(6,666)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	46
Total other comprehensive (loss) income	7,813	(10,086)	(6,620)
Balance at end of period	$ (8,948)	$ (16,761)	$ (6,675)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) - Reclassifications out of Accumulated Other Comprehensive Income/(Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amount Reclassified from Accumulated Other Comprehensive Income
Income before Income Taxes	$ (469,765)	$ (374,825)	$ (334,704)
Tax benefit	95,587	90,649	95,149
Miscellaneous income (expense), net	(3,265)	(3,212)	4,799
Net Income	(374,178)	(284,176)	(239,555)
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income	370	771	6,432
Defined Benefit Pension Plans | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	201	914	8,358
Amortization of prior service cost	349	177	177
Income before Income Taxes	550	1,091	8,535
Tax benefit	(180)	(320)	(2,149)
Net Income	370	771	6,386
Derivatives | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income	0	0	46
Derivatives | Changes in cross currency swap: interest component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	0	0	(171)
Derivatives | Changes in cross currency swap: foreign exchange component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Miscellaneous income (expense), net	$ 0	$ 0	$ 217

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands, € in Millions	Jul. 06, 2022 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 06, 2022 USD ($)	Jul. 06, 2022 EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		$ 572	$ 386
Derivative Liabilities		12,473	22,420
Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		572	386
Derivative Liabilities		622	221
Cross Currency Swap Contract | Accounts payable and accrued liabilities | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		0	0
Cross Currency Swap Contract | Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, term of contract	7 years
Amount hedged				$ 203,000	€ 200
Derivative, fixed interest rate				2.5224%	2.5224%
Derivative, annual fixed interest payments receivable				$ 3,700
Cash flow hedge derivative instrument liability at fair value		11,900
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		69,900
Foreign Exchange Contracts | Prepaid and other | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		572	386
Foreign Exchange Contracts | Accounts payable and accrued liabilities | Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		$ 622	$ 221
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.7 million
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate on notes (as a percent)		3.60%		3.60%	3.60%
Debt instrument, face amount				$ 400,000
Debt instrument, periodic payment | €	€ 2.5

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value of Derivative Instruments
Derivative Assets	$ 572	$ 386
Derivative Liabilities	12,473	22,420
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivative Liabilities	11,851	22,199
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	0	0
Derivatives Designated as Hedging Instruments | Cross Currency Swap Contract | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	11,851	22,199
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	572	386
Derivative Liabilities	622	221
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	572	386
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	622	221
Derivatives not Designated as Hedging Instruments | Cross Currency Swap Contract | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivative Instruments on the Consolidated Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative instruments, gain or (loss)
Miscellaneous income (expense), net	$ 3,265	$ 3,212	$ (4,799)
Amount of (Loss) Gain Recognized in Income on Derivatives	(190)	(668)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	7,813	(10,086)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0
Changes in cross currency swap: foreign exchange component | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative	7,813	(10,086)
Miscellaneous income (expense), net	3,265
Changes in cross currency swap: foreign exchange component | Miscellaneous, net | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative	0	0
Foreign Exchange Contracts
Derivative instruments, gain or (loss)
Amount of (Loss) Gain Recognized in Income on Derivatives	$ (190)	$ (668)

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Derivative Assets
Gross Amount	$ 572	$ 386
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	572	386
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 572	$ 386
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid and other	Prepaid and other
Derivative Liabilities
Gross Amount	$ 12,473	$ 22,420
Gross Amounts Offset in the Statement of Financial Position	0	0
Net Amounts Presented in the Statement of Financial Position	12,473	22,420
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments	0	0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received	0	0
Net Amount	$ 12,473	$ 22,420
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities

FAIR VALUE - Financial Assets a

FAIR VALUE - Financial Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Assets
Investment in equity securities	$ 2,986	$ 1,106
Foreign exchange contracts	572	386
Convertible notes	5,650	5,650
Total assets at fair value	9,208	7,142
Liabilities
Foreign exchange contracts	622	221
Cross currency swap contract	11,851	22,199
Total liabilities at fair value	12,473	22,420
Level 1
Assets
Investment in equity securities	2,986	1,106
Foreign exchange contracts	0	0
Convertible notes	0	0
Total assets at fair value	2,986	1,106
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	0	0
Level 2
Assets
Investment in equity securities	0	0
Foreign exchange contracts	572	386
Convertible notes	0	0
Total assets at fair value	572	386
Liabilities
Foreign exchange contracts	622	221
Cross currency swap contract	11,851	22,199
Total liabilities at fair value	12,473	22,420
Level 3
Assets
Investment in equity securities	0	0
Foreign exchange contracts	0	0
Convertible notes	5,650	5,650
Total assets at fair value	5,650	5,650
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Total liabilities at fair value	$ 0	$ 0

FAIR VALUE - Narrative (Details

FAIR VALUE - Narrative (Details) - USD ($) $ in Billions	Dec. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair value of long-term obligations	$ 0.6	$ 0.6

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024
Commitments and contingencies
Unconditional purchase commitment		$ 46,100,000
Purchase commitment, term		4 years
Liabilities recorded under indemnification agreements		$ 0
Gain (loss) related to litigation settlement	$ 6,600,000
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements		0
Tax Assessment
Commitments and contingencies
Liabilities recorded under indemnification agreements		0
Estimated loss contingency		12,000,000
Tax Assessment Interest and Penalties | Minimum
Commitments and contingencies
Estimated loss contingency		15,000,000
Tax Assessment Interest and Penalties | Maximum
Commitments and contingencies
Estimated loss contingency		$ 16,000,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 10, 2024
Stock repurchase program
Common stock repurchased (retired and held in treasury) (in shares)	433	399	860
Common stock repurchased (retired and held in treasury)	$ 68.6	$ 47.6	$ 92.1
Remaining authorized repurchase amount	$ 462.7
Stock Repurchase Program October 10, 2024
Stock repurchase program
Share repurchases authorized amount				$ 500

CAPITAL STOCK (Details)

CAPITAL STOCK (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Authorized common stock (in shares)	199,000,000	199,000,000
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	71,700,000
Balance at the end of the year (in shares)	72,500,000	71,700,000
Cash dividends paid on the common stock	$ 114,055	$ 103,683	$ 99,461
Common Shares
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	71,679,658	70,848,810	70,370,812
Restricted stock vestings (in shares)	150,849	150,970	176,535
Balance at the end of the year (in shares)	72,466,548	71,679,658	70,848,810
Common Shares | Employee option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	629,541	679,878	301,463
Common Shares | Director option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	6,500	0	0
Treasury Shares
Common stock and treasury stock and the share activity
Balance at the beginning of the year (in shares)	5,775,295	5,555,027	4,852,709
Common stock repurchased (in shares)	432,600	398,594	860,000
Balance at the end of the year (in shares)	6,015,772	5,775,295	5,555,027
Treasury Shares | Employee option exercises
Common stock and treasury stock and the share activity
Stock option exercises (in shares)	192,123	178,326	157,682

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average fair value of stock options granted (in dollars per share)	$ 36.07
Options granted, Weighted average exercise price per share (in dollars per share)	$ 141
Proceeds from stock option exercises	$ 54,809	$ 53,983	$ 28,512
Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average fair value of stock options granted (in dollars per share)		$ 19.84
Received stock options exercise price percentage		110%
Non Executive Officer Employees
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average fair value of stock options granted (in dollars per share)		$ 24.23
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSUs granted (in shares)	130,098
Restricted stock vestings (in shares)	184,631
Time-Based RSUs | Director option exercises
Share-based Compensation Arrangement by Share-based Payment Award
RSUs granted (in shares)	10,208
Restricted stock vestings (in shares)	11,508
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSUs granted (in shares)	129,614
Restricted stock vestings (in shares)	97,686
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 7,600	$ 5,900	8,000
Unrecognized compensation expense	$ 44,900
Weighted-average period cost will be recognized over	1 year 9 months 18 days
Options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 13,200	9,100	4,400
Unrecognized compensation expense	$ 4,500
Weighted-average period cost will be recognized over	1 year 9 months 18 days
Expiration period (in years)	10 years
Proceeds from stock option exercises	$ 54,800	$ 54,000	$ 28,500
Options | Director option exercises
Share-based Compensation Arrangement by Share-based Payment Award
Options granted, Weighted average exercise price per share (in dollars per share)	$ 0

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 145.79	$ 116.17	$ 141.95
Grant date stock price (in dollars per share)	$ 141	$ 111.38	$ 114.52
Aptar's stock price expected volatility	18.80%	20%	20.20%
Expected average volatility of peer companies	34.80%	39.70%	41.70%
Correlation assumption	30.70%	33.30%	41.20%
Risk-free interest rate	4.51%	3.83%	2.04%
Dividend yield assumption	1.16%	1.36%	1.33%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Time-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) | shares	335,874
RSUs granted (in shares) | shares	130,098
RSUs vested (in shares) | shares	(184,631)
RSUs forfeited (in shares) | shares	(4,096)
Nonvested outstanding ending balance (in shares) | shares	277,245
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 115.15
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	138.24
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	119.11
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	119.31
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 123.28
Performance-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) | shares	514,383
RSUs granted (in shares) | shares	129,614
RSUs vested (in shares) | shares	(97,686)
RSUs forfeited (in shares) | shares	(33,085)
Nonvested outstanding ending balance (in shares) | shares	513,226
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) | $ / shares	$ 130.10
Granted, Weighted average grant date fair value (in dollars per share) | $ / shares	145.79
Vested, Weighted average grant date fair value (in dollars per share) | $ / shares	162.24
Forfeited, Weighted average grant date fair value (in dollars per share) | $ / shares	142.78
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) | $ / shares	$ 127.17

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 40,581	$ 37,015	$ 40,937
Fair value of units vested	36,313	29,100	32,013
Intrinsic value of units vested	40,083	33,914	33,024
Options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	7,069	4,278	0
Compensation expense, net of tax	6,880	4,278	0
Grant date fair value of options vested	2,320	2,663	0
Options | Compensation expense (included in SG&A)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	6,381	3,929	0
Options | Compensation expense (included in Cost of sales)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 688	$ 349	$ 0

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Stock option weighted average exercise price
Options granted, Weighted average exercise price per share (in dollars per share)	$ 141
Options | Stock Awards Plans
Assumptions used to estimate fair value of stock options granted
Dividend Yield	1.28%	1.41%
Expected Stock Price Volatility	17.03%	16.55%
Risk-free Interest Rate	4.51%	3.57%
Expected Life of Option (years)	7 years	7 years
Stock options activity
Outstanding at the beginning of the period (in shares)	2,182,784
Granted (in shares)	249,805
Exercised (in shares)	(750,771)
Forfeited or expired (in shares)	(18,511)
Outstanding at the end of the period (in shares)	1,663,307	2,182,784
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 80.63
Options granted, Weighted average exercise price per share (in dollars per share)	141
Options exercised, Weighted average exercise price per share (in dollars per share)	71.62
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	87.66
Outstanding at the end of the period (in dollars per share)	$ 93.69	$ 80.63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	1,211,208
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 80.20
Options outstanding, Weighted average remaining contractual term (in years)	4 years 2 months 12 days
Options exercisable, Weighted average remaining contractual term (in years)	2 years 6 months
Options outstanding, Aggregate intrinsic value (in USD)	$ 105,470
Options exercisable, Aggregate intrinsic value (in USD)	93,145
Options exercised, Intrinsic value, at end of period	$ 57,259	$ 38,706	$ 20,608
Options | Director option exercises
Stock options activity
Outstanding at the beginning of the period (in shares)	19,000
Granted (in shares)	0
Exercised (in shares)	(19,000)
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	0	19,000
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 66.59
Options granted, Weighted average exercise price per share (in dollars per share)	0
Options exercised, Weighted average exercise price per share (in dollars per share)	66.59
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 0	$ 66.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	0
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 0
Options outstanding, Weighted average remaining contractual term (in years)	0 years
Options exercisable, Weighted average remaining contractual term (in years)	0 years
Options outstanding, Aggregate intrinsic value (in USD)	$ 0
Options exercisable, Aggregate intrinsic value (in USD)	0
Options exercised, Intrinsic value, at end of period	$ 1,394	$ 1,978	$ 0

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income (Numerator)
Income available to common stockholders, basic	$ 374,541	$ 284,487	$ 239,288
Income available to common stockholders, diluted	$ 374,541	$ 284,487	$ 239,288
Shares (Denominator)
Basic (in shares)	66,334	65,616	65,402
Total average equivalent shares (in shares)	67,691	66,905	66,719
Per Share Amount
Net income per share, basic (in dollars per share)	$ 5.65	$ 4.34	$ 3.66
Net income per share, diluted (in dollars per share)	$ 5.53	$ 4.25	$ 3.59
Stock options
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	765	874	978
Restricted stock
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	592	415	339

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details) - segment		12 Months Ended
	Jan. 01, 2023	Dec. 31, 2024
Segment Reporting [Abstract]
Number of combined segments	1
Number of realigned segments	2
Number of reportable segments	3	3

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Financial information regarding the Company's reportable segments
Net Sales	$ 3,582,890	$ 3,487,450	$ 3,322,249
Selling, Research & Development and Administrative:	582,226	565,783	544,262
Acquisition-related costs	140	480	231
Restructuring initiatives	13,002	45,004	6,597
Curtailment gain related to restructuring initiatives	1,851	0	0
Net unrealized investment gain (loss)	1,713	(2,775)	(3,323)
Depreciation and amortization	(263,784)	(248,593)	(233,706)
Interest Expense	(43,898)	(40,418)	(40,827)
Interest Income	12,101	4,373	2,700
Income before Income Taxes	469,765	374,825	334,704
Capital Expenditures	276,481	312,342	310,427
Total Assets	$ 4,432,278	4,451,890	4,203,458
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Miscellaneous income (expense), net
Optimization initiative
Financial information regarding the Company's reportable segments
Restructuring initiatives	$ 13,019	45,445	6,224
Prior year initiatives
Financial information regarding the Company's reportable segments
Restructuring initiatives	(17)	(441)	373
Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	1,643,152	1,520,993	1,361,256
Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	1,225,730	1,267,697	1,222,535
Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	714,008	698,760	738,458
Operating Segments
Financial information regarding the Company's reportable segments
Net Sales	3,618,480	3,526,161	3,366,522
Adjusted EBITDA	842,422	770,042	679,618
Depreciation and amortization	(260,686)	(244,860)	(227,760)
Capital Expenditures	258,598	332,115	282,822
Total Assets	4,196,204	4,289,912	4,051,310
Operating Segments | Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	1,644,012	1,521,837	1,372,449
Cost of Sales (exclusive of depreciation and amortization):	834,595	797,542	709,873
Selling, Research & Development and Administrative:	241,357	221,808	211,101
Other Segment Items:	(1,171)	(990)	(1,340)
Adjusted EBITDA	568,371	502,633	441,622
Restructuring initiatives	589	4,852	0
Depreciation and amortization	(120,429)	(109,366)	(94,396)
Capital Expenditures	148,261	196,083	164,396
Total Assets	2,057,586	2,111,779	1,872,843
Operating Segments | Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	1,252,904	1,297,477	1,246,018
Cost of Sales (exclusive of depreciation and amortization):	884,433	922,223	891,619
Selling, Research & Development and Administrative:	183,903	192,831	180,910
Other Segment Items:	(2,515)	(11,073)	(1,881)
Adjusted EBITDA	159,909	163,716	151,887
Restructuring initiatives	8,041	20,683	5,539
Depreciation and amortization	(82,931)	(83,399)	(80,498)
Capital Expenditures	64,571	83,872	74,203
Total Assets	1,392,491	1,412,203	1,398,813
Operating Segments | Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	721,564	706,847	748,055
Cost of Sales (exclusive of depreciation and amortization):	511,409	507,866	560,300
Selling, Research & Development and Administrative:	89,913	87,930	92,697
Other Segment Items:	(1,456)	(729)	(648)
Adjusted EBITDA	114,142	103,693	86,109
Restructuring initiatives	3,835	17,927	1,058
Depreciation and amortization	(57,326)	(52,095)	(52,866)
Capital Expenditures	45,766	52,160	44,223
Total Assets	746,127	765,930	779,654
Intersegment
Financial information regarding the Company's reportable segments
Net Sales	(35,590)	(38,711)	(44,273)
Intersegment | Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales	(860)	(844)	(11,193)
Intersegment | Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales	(27,174)	(29,780)	(23,483)
Intersegment | Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales	(7,556)	(8,087)	(9,597)
Corporate & Other
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(67,498)	(62,320)	(62,930)
Restructuring initiatives	537	1,542	0
Depreciation and amortization	(3,098)	(3,733)	(5,946)
Capital Expenditures	23,630	14,729	29,491
Total Assets	236,074	161,978	152,148
Transfer of Corporate Expenditures
Financial information regarding the Company's reportable segments
Capital Expenditures	$ (5,747)	$ (34,502)	$ (1,886)

SEGMENT INFORMATION - Summary_2

SEGMENT INFORMATION - Summary of Net Sales and Long-Lived Assets By Geographic Area (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Net sales and long-lived asset information by geographic area
Net Sales	$ 3,582,890	$ 3,487,450	$ 3,322,249
Property, Plant and Equipment, Net	$ 1,447,150	$ 1,478,063	$ 1,343,664
Customer Concentration Risk | Net sales
Net sales and long-lived asset information by geographic area
Concentration risk, threshold percentage	0.04	0.05	0.05
United States
Net sales and long-lived asset information by geographic area
Net Sales	$ 1,037,968	$ 949,248	$ 972,920
Property, Plant and Equipment, Net	349,255	357,729	346,382
Europe
Net sales and long-lived asset information by geographic area
Net Sales	1,769,868	1,805,725	1,616,176
Property, Plant and Equipment, Net	867,840	882,702	772,828
France
Net sales and long-lived asset information by geographic area
Net Sales	499,795	541,333	487,650
Property, Plant and Equipment, Net	527,570	550,738	482,091
Germany
Net sales and long-lived asset information by geographic area
Net Sales	169,891	160,812	163,277
Property, Plant and Equipment, Net	229,637	225,860	194,898
Italy
Net sales and long-lived asset information by geographic area
Net Sales	180,101	200,817	149,725
Property, Plant and Equipment, Net	44,087	42,240	42,522
Spain
Net sales and long-lived asset information by geographic area
Net Sales	171,779	175,101	149,987
Other Europe
Net sales and long-lived asset information by geographic area
Net Sales	748,302	727,662	665,537
Property, Plant and Equipment, Net	66,546	63,864	53,317
China
Net sales and long-lived asset information by geographic area
Net Sales	155,502	146,026	177,855
Property, Plant and Equipment, Net	105,613	112,017	98,469
Other Foreign Countries
Net sales and long-lived asset information by geographic area
Net Sales	619,552	586,451	555,298
Property, Plant and Equipment, Net	$ 124,442	$ 125,615	$ 125,985

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) - USD ($)			12 Months Ended
	Aug. 01, 2023	Mar. 01, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow			$ 0	$ 16,570,000	$ 4,100,000
Acquisition-related costs			140,000	480,000	231,000
Goodwill			936,256,000	963,418,000	$ 945,632,000
Hengyu Acquisition
Acquisitions
Payments to acquire businesses, gross	$ 5,200,000
iD SCENT and Gulf Closures
Acquisitions
Acquisition-related costs				300,000
iD SCENT
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		$ 9,400,000
Cash acquired		1,400,000
Gulf Closures
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		1,500,000
Cash acquired		$ 1,200,000
Percentage of interest acquired		80%
Valuation of full company equity of acquired company		$ 3,300,000
Non-controlling interest value		$ 700,000
2024 Acquisitions
Acquisitions
Goodwill deductible for tax purposes			$ 0
2023 Acquisitions
Acquisitions
Goodwill				3,800,000
Goodwill deductible for tax purposes				0
2023 Acquisitions | Aptar Beauty
Acquisitions
Goodwill				3,700,000
2023 Acquisitions | Aptar Closures
Acquisitions
Goodwill				$ 100,000

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 146,269	$ 49,203
Goldrain
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	96,667	0
BTY
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	32,047	33,090
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	4,712	4,751
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	948	905
PureCycle
Schedule of Equity Method Investments [Line Items]
Other Investments	2,986	1,106
YAT
Schedule of Equity Method Investments [Line Items]
Other Investments	5,206	5,352
Loop
Schedule of Equity Method Investments [Line Items]
Other Investments	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other Investments	$ 809	$ 1,105

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands						12 Months Ended				60 Months Ended
	Oct. 22, 2024 USD ($)	Apr. 26, 2024 USD ($)	Jul. 07, 2021 USD ($)	Apr. 01, 2020 USD ($)	Jan. 01, 2020 USD ($) company	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2009 EUR (€)	Dec. 31, 2023 USD ($)	Mar. 31, 2021
Schedule of Equity Method Investments [Line Items]
Investment impairment						$ 0
Goldrain
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment	40%
Investment in unconsolidated affiliate	$ 99,000,000
Equity method investment, underlying equity in net assets						82,700,000
Equity method investment, difference between carrying amount and underlying equity						$ 14,700,000
Weighted average useful life (in years)						11 years 9 months 18 days
BTY
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					49%
Investment in unconsolidated affiliate					$ 32,000,000
Equity method investment, underlying equity in net assets						$ 21,700,000
Equity method investment, difference between carrying amount and underlying equity						$ 3,500,000
Weighted average useful life (in years)						13 years 10 months 24 days
Number of companies acquired | company					3
Initial lock-up period (in years)					5 years
Second lock-up period (in years)					3 years
Purchases from related party						$ 11,400,000	$ 14,300,000	$ 11,400,000
Accounts payable, accrued and other liabilities						$ 2,500,000	$ 1,800,000			$ 1,800,000
BTY | Minimum | Call Option
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					26%
BTY | Maximum | Call Option
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment					31%
Sonmol
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment				30%
Investment in unconsolidated affiliate				$ 5,000,000
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Ownership percentage of equity method investment									23%
Investment in unconsolidated affiliate | €									€ 574
Loop | Preferred equity stocks
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated affiliate										2,900,000
PureCycle
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage											0.01
PureCycle | Preferred equity stocks
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated affiliate										3,000,000
Equity received in exchange for services		$ 200,000								$ 700,000
Number of shares sold (in shares) | shares						0	510,449	157,600
YAT
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated affiliate			$ 5,900,000
Investment ownership percentage			0.10

INVESTMENT IN EQUITY SECURITI_5

INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Proceeds	$ 0	$ 5,604	$ 1,599
PureCycle | Preferred stock
Schedule of Equity Method Investments [Line Items]
Shares Sold (in shares)	0	510,449	157,600
Proceeds		$ 5,604	$ 1,599
Realized Gain		$ 4,188	$ 1,213

INVESTMENT IN EQUITY SECURITI_6

INVESTMENT IN EQUITY SECURITIES - Net Investment Gain/Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Net investment gain (loss)	$ 1,713	$ 1,413	$ (2,110)
PureCycle | Preferred stock
Schedule of Equity Method Investments [Line Items]
Net investment gain (loss)	$ 1,713	$ 1,413	$ (2,110)

RESTRUCTURING INITIATIVES - Nar

RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring initiatives
Restructuring charges	$ 13,002	$ 45,004	$ 6,597
Optimization Plan
Restructuring initiatives
Restructuring charges	13,000	$ 45,400	$ 6,200
Cumulative expense incurred	$ 64,700

RESTRUCTURING INITIATIVES - Res

RESTRUCTURING INITIATIVES - Restructuring Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring reserve
Restructuring initiatives	$ 13,002	$ 45,004	$ 6,597
Business Optimization
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	29,888	4,993
Restructuring initiatives	13,019	45,445
Cash Paid	(32,350)	(18,094)
Interest and FX Impact	(600)	(2,456)
Restructuring reserve, balance at the end of the period	9,957	29,888	4,993
Business Optimization | Employee severance
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	27,078	4,993
Restructuring initiatives	6,562	37,167
Cash Paid	(23,791)	(12,608)
Interest and FX Impact	(688)	(2,474)
Restructuring reserve, balance at the end of the period	9,161	27,078	4,993
Business Optimization | Professional fees and other costs
Restructuring reserve
Restructuring reserve, balance at the beginning of the period	2,810	0
Restructuring initiatives	6,457	8,278
Cash Paid	(8,559)	(5,486)
Interest and FX Impact	88	18
Restructuring reserve, balance at the end of the period	$ 796	$ 2,810	$ 0

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
VALUATION AND QUALIFYING ACCOUNTS
Valuation allowance for deferred tax asset, tax losses not previously expected to be realized	$ 29,500
Increase in unrecognized tax benefits is reasonably possible	11,000
CECL
VALUATION AND QUALIFYING ACCOUNTS
Balance at Beginning Of Period	16,217	$ 9,519	$ 7,374
Charged to Costs and Expenses	1,016	8,077	3,213
Charged to Other Accounts	0	12	0
Deductions from Reserve	(1,448)	(1,391)	(1,068)
Balance at End of Period	15,785	16,217	9,519
Deferred tax valuation allowance
VALUATION AND QUALIFYING ACCOUNTS
Balance at Beginning Of Period	48,856	46,239	47,149
Charged to Costs and Expenses	1,739	1,498	3,754
Charged to Other Accounts	26,903	2,495	380
Deductions from Reserve	(16,364)	(1,376)	(5,044)
Balance at End of Period	$ 61,134	$ 48,856	$ 46,239